Immunogenicity of biological drugs in inflammatory rheumatic disease: Clinical relevance and therapeutic drug monitoring by Plasencia Rodríguez, Chamaida
 1 
 
 
UNIVERSIDAD AUTÓNOMA DE MADRID 
FACULTAD DE MEDICINA 
 
TRABAJO DE TESIS DOCTORAL 
DOCTORAL THESIS WORK 
 
 
 
 
 
 
 
 
“IMMUNOGENICITY OF BIOLOGICAL DRUGS IN 
INFLAMMATORY RHEUMATIC DISEASES: CLINICAL 
RELEVANCE AND THERAPEUTIC DRUG 
MONITORING” 
 
CHAMAIDA PLASENCIA RODRÍGUEZ 
MADRID 2017 
 3 
 
 
 
 
 
 
 
To Germán and Sara 
 
 
 
 
 
 
 
 7 
 
Acknowledgements 
First, I wanted to dedicate this thesis to the patients because they are the main motivation 
of this work with the intention to improve the management of their disease and their quality of 
life. 
I wanted to thank my family because they have always been at my side supporting my 
decisions. Firstly, some words for my mother and my sister who have given me an unconditional 
support to follow my life-path. To Gracibel and Paco, thanks to them this thesis has been able to 
be written. Finally, to Germán and Sara, two gifts of life. 
This work has become a reality thanks to my thesis directors. In particular, I wanted to 
have a few words for Alejandro Balsa and Dora Pascual-Salcedo. They are two admirable 
professionals, with concerns and nonconformities that have awakened in me the interest to do 
research and the desire to do things well. Personally, I feel very fortunate to have these two 
people close to me.  
I still remember the first annoyance from Emilio Martín-Mola when I sent someone an 
abstract to the EULAR Congress without consulting previously and it was accepted as an oral 
communication in my second year of residence. He has taught me so much during years and he 
has always been available to guide me professionally. 
I would like to thank the management team of La Paz Hospital, for creating the “Proyecto 
REX”, which allows professionals trained in this hospital to improve and innovate at 
professional level. 
Of course, this work could never have been possible without the help and support of the 
entire Rheumatology Service of La Paz Hospital, from rheumatologists, residents, nurses, 
assistants, secretaries and clinical trial coordinator. 
I have spent a considerable period of my carrier in the Immunology Unit, under the 
supervision of Dr. Pascual-Salcedo, surrounded by wonderful professionals who have taught me 
a lot. In particular I wanted to name: Ana, Teresa, Andrea, Borja, Maria Teresa, Eva, Maria 
Jesus, Cristina, Susana, Maika, Araceli, María Ángeles and Rita. 
 8 
 
In Amsterdam, during my fellowship, I met a great professional team at Reade and 
Sanquin who taught me a lot, even to ride a bicycle. From this stay, I want to highlight a very 
special person for me who is Samina. Thanks to her, my life was much easier and fun there. 
To my residence mate, Leticia Lojo, I want to thank many things, but mainly that beside 
her the work was easier and more fun and I cannot forget that my subway trips were very 
entertaining. 
I wanted to make a special mention to Gema Bonilla, who besides to being one of my 
professional references; she has always been a very important personal support in Madrid. 
When I started my residence at La Paz Hospital, one of my first co-workers was Mariana 
and since then she has been part of my life. In addition, she was the first person to introduce me 
on research with a work on ANCA positive vasculitis. 
When I arrived to Madrid ten years ago, I did not know anybody. During the residence, I 
was very fortunate to meet some residence mates who have become great friends and have made 
me feel at home. Thanks to Nuria, Nany, Zena, Eli, Cris, María, Pili and Lucía for all those fun 
times together.  
Andrea Jochems has been a great help in the development of this thesis and she has 
become almost an expert in biological therapies in rheumatic patients.  
Last but not least important, I did not want to end these acknowledgements without 
mentioning two crucial people for me with whom I have shared good and bad moments. They 
are Nereida and Beatriz who are close to me even though we are many kilometers apart. 
 
 
 
 
 
 
 9 
 
ABSTRACT 
In the present thesis work, we show the data from a research line about the 
immunogenicity of biologics and its clinical relevance in rheumatic patients under biological 
therapy. This research was motivated due to the clinical observation that a significant percentage 
of patients lost treatment efficacy to treatment with biological drugs, despite an initial good 
response and that they continued with the same treatment regimen. Then, our purpose was to 
investigate which factors influenced on this treatment failure.  
Our first studies were carried out in rheumatoid arthritis (RA) and Spondyloarthritis 
(SpA) patients under infliximab (Ifx) therapy. In these works, we demonstrated that lower Ifx 
levels and/or detectable ATI were associated with a poor clinical response. In addition, it was 
seen that patients receiving methotrexate (MTX) co-therapy less frequently developed antibodies 
to Ifx (ATI) or showed lower ATI levels than patients under monotherapy. Another important 
aspect was that ATI development was associated with treatment survival and with the incidence 
of adverse events such as infusion related reactions. The association between drug levels and 
clinical outcomes was also evaluated with other biological drugs such as golimumab and 
tocilizumab.  
Later, we noticed that serum trough drug and anti-drug antibodies (ADA) monitoring to 
the first TNFi could have an influence on future therapeutic decisions. On the other hand, we 
saw that Ifx intensification strategies have a limited effect and are not associated with a 
significant clinical improvement.  
We made a review on tapering or discontinuation strategies in SpA patients, concluding 
that tapering strategy is successful in SpA with low disease activity but discontinuation strategies 
are not recommended because they lead to flare in most cases. Two observational studies 
comparing the tapering strategy with the standard therapy regimen in RA and SpA patients were 
performed. Both show that tapering is feasible in clinical practice with similar clinical evolution 
than patients under a standard therapy regimen.  
Finally, we carried out two studies demonstrating that adequate clinical monitoring 
together with tools such as drug monitoring support the treatment optimization, in order to treat 
patients more safely and with a significant reduction of costs. 
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RESUMEN 
Esta tesis doctoral trata sobre la inmunogenicidad de las terapias biológicas y su 
relevancia clínica en pacientes con enfermedades reumáticas. Esta investigación fue motivada 
por la observación clínica de que un porcentaje significativo de pacientes perdía eficacia del 
tratamiento a pesar de una buena respuesta inicial y de continuar con el mismo régimen 
terapéutico. Entonces, nos propusimos analizar qué factores podrían influir en el aclaramiento 
del fármaco.  
Nuestros primeros estudios se realizaron en pacientes con artritis reumatoide (AR) y 
espondiloartritis (SpA) tratados con infliximab (Ifx). Se demostró que los pacientes con niveles 
séricos más bajos de Ifx y/o presencia de anticuerpos anti-infliximab (ATI) se tenían una peor 
respuesta clínica. También se observó que los pacientes que recibían simultáneamente 
metotrexato (MTX) presentaban con menor frecuencia ATI en el suero o se detectaban niveles 
más bajos de ATI que en los pacientes en monoterapia. El desarrollo de ATI se asoció con una 
peor supervivencia de Ifx y con mayor incidencia de eventos adversos como reacciones 
relacionadas con la infusión. La asociación entre los niveles de fármaco y los resultados clínicos 
también se evaluó con otros biológicos como golimumab y tocilizumab 
Observamos que la monitorización de niveles séricos de fármaco y/o anticuerpos frente al 
fármaco contra el primer TNFi podría influir en futuras decisiones terapéuticas. Por otra parte, 
vimos que las intensificaciones de tratamiento con Ifx tienen un efecto limitado y no está 
asociada con una mejora clínica significativa. 
En una revisión sobre las estrategias de optimización o discontinuación en los pacientes 
de SpA objetivamos que la estrategia de optimización de dosis es factible en SpA con baja 
actividad, pero la estrategia de suspensión no se recomienda porque conduce al desarrollo de 
brotes en la mayoría de los casos. Se realizaron dos estudios observacionales que compararon la 
estrategia de optimización frente al régimen de terapia estándar en pacientes con AR y SpA. 
Ambos muestran que la estrategia de disminución de dosis es factible en la práctica clínica con 
una evolución clínica similar a los pacientes bajo un régimen de terapia estándar. 
Por último, se realizaron dos estudios que demuestran que un seguimiento clínico 
adecuado junto con herramientas como el control de los niveles séricos de fármacos pueden 
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ayudar a que las estrategias de optimización se lleven a cabo de manera más segura con una 
reducción significativa de costes. 
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Aba: Abatacept 
ACPA: Anti-citrullinated peptide antibodies 
Ada: Adalimumab 
ADA: Anti-drug antibodies 
ADA +: Anti-drug antibodies positive 
ADA-: Anti-drug antibodies negative 
ANA: antinuclear antibodies  
Anti-TNF: Anti tumor necrosis factor 
AS: Ankilosing spondylitis 
ASAS-20: Assessment in Ankylosing Spondylitis response criteria 
ASDAS: Ankylosing spondylitis disease activity score 
AU: arbitrary units  
AUC: area under the curve  
AxSpA: axial SpA  
BASDAI: Bath ankylosing spondylitis disease activity index 
BMI: body mass index  
Certo: Certolizumab 
CD: Crohn disease 
DAS28: Disease activity score 28 
DMARDs: Disease modifying anti-rheumatic drugs  
ELISA: Enzyme-linked immunosorbent assay 
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Etn: Etanercept 
ESR: erythrocyte sedimentation rate  
EULAR: European league against rheumatism 
Goli: Golimumab 
HAMA: human antimouse antibodies  
HACA: human antichimeric antibodies  
HDQ: hydroxycloroquine  
HAHA: human antihuman antibodies  
HMSA: homogeneus mobility shift assay 
HPE: high performance ELISA  
iv: intravenously 
LOCF: Last observation carried forward  
NSAIDs: non steroidal anti-inflammatory drugs 
nraxSpA: non radiographic axSpA 
PsA: Psoriatic Arthritis 
PIA: pH-shift-anti-Idiotype Antigen binding test  
PICOS: Population, Intervention, Comparison, Outcome and Study design 
PK: pharmacokinectic 
polyHRP: streptavidin-polyperoxidase 
RA: Rheumatoid arthritis 
RIA: Radioimmunoassay 
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RF: Rheumatoid factor 
RGA: reporter gene assay  
ROC: receiver operating characteristic  
Rtx: Rituximab 
sc: subcutaneously 
SpA: Spondyloarthritis 
SpA associated to IBD: SpA associated to inflammatory bowel diseases 
SSZ: sulphasalazine 
TMB: tetramethylbenzidine  
TNF: tumor necrosis factor 
TNFα: tumor necrosis factor alpha 
TNFi: tumor necrosis factor inhibitors 
Tcz: Tocilizumab 
vs: versus 
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Efficacy of the biological inhibitors of TNF in rheumatic 
diseases 
 
The rheumatic diseases such as rheumatoid arthritis (RA), seronegative 
spondyloarthropathies (SpA) and psoriatic arthritis (PsA) are chronic inflammatory disorders 
that lead to an important functional disability(1–3). The prognosis of these inflammatory 
disorders has changed considerably along with the introduction of biological drugs(4). Biological 
drugs are protein macromolecules whose active principle is produced or derived from a living 
organism and are made by means of recombinant DNA and / or controlled gene expression 
methods(4). The first biological drugs to be developed were directed to neutralize the tumor 
necrosis factor alpha (TNF (Figure 1). 
 
 
 
Nowadays, there are five tumor necrosis factor inhibitors (TNFi) available, of whom 
three are monoclonal antibodies [Infliximab (Ifx), Adalimumab (Ada) and Golimumab (Goli)]. 
One is a pegilated F(ab)2 fragment of a humanized monoclonal antibody Certolizumab (Ctz) and 
the other is a fusion protein between 2 molecules of the TNF receptor extracellular domain (p75) 
and the constant portion of a IgG1 immunoglobulin, known as Etanercept (Etn)(5–10). 
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Moreover, more biological drugs with another mechanism of action have emerged in the last 
years, such as Rituximab (Rtx), an anti-CD20 chimeric antibody(11); Abatacept (Aba), an anti-
CD80/anti-CD86 fusion protein(12); Tocilizumab (Tcz), a humanized anti-interleukin-6 receptor 
antibody(13); Secukinumab (Secu), a monoclonal anti-IL17 antibody and Ustekinumab (Uste), a 
monoclonal anti-IL12/23 antibody(14–17) (Figure 2).  
 
 
 
The efficacy of the TNFi biopharmaceuticals in the treatment of inflammatory diseases 
have been demonstrated in many studies, showing that a considerable proportion of patients 
under treatment with these drugs reach a lower disease activity or remission(5,6,8–10). However, 
some patients do not improve during induction therapy phase (primary response failure), while 
others present an initial good clinical response that is lost later on during treatment (secondary 
response failure). In rheumatic diseases such as RA under TNFi, it has been described that 
approximately one third of patients suffer a primary response failure(18). This situation normally 
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leads to intensifying therapy strategies with the consequent increasing therapy costs and risks of 
adverse events(18).  
Up to 50% of patients with chronic inflammatory disease, such as RA or Crohn disease 
treated with TNFi eventually lose response to the biological drugs(19,20). The underlying 
mechanisms involved in the TNFi failure are not completely understood. Several factors can 
relate to this behaviour, like differences in the drug bioavailability and drug PK, as well as 
pharmacodynamic issues involving the basic mechanisms that drive inflammation in the affected 
tissues(18).  
These findings have motivated a great scientific interest in the last years that attempt to 
define factors that can affect the bioavailability and pharmacokinetic (PK) of the biological 
therapies in order to use the most effective therapeutic strategies in patients with chronic 
inflammatory diseases(21–27).  
 
Influencing factors on the efficacy of the biopharmaceuticals 
 
As a result of research in the recent years, some factors are known to influence the 
biological drug efficacy. Among the main factors are the body mass index (BMI), smoking 
habits, serotype (in RA patients), serum trough drug levels and the concomitant therapy with 
disease modifying anti-rheumatic drugs (DMARDs)(28–32) (Figure 3).  
RA patients with high BMI seem to have a poorer clinical response. Adipose tissue itself 
has pro-inflammatory characteristics, which in addition to the disease activity negatively 
influence the therapy outcome in RA patients(33). In the METEOR cohort(28), obese RA 
patients were significantly less likely to be in low disease activity. Similar findings were 
observed in an early RA cohort (CATCH study), where an inverse relation between increased 
BMI, from overweight to obesity, and the likelihood of achieving remission was seen. In the 
GISEA registry, obese RA patients under TNFi were significantly more likely to fail reaching 
remission at one year (28).  
Smoking habit has demonstrated to be associated to extra-articular manifestations, 
radiographic progression and clinical response to DMARDs in RA patients. Similar correlation 
has been shown between smoker RA patients and TNFi treatment response(34,35). In a Swedish 
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early RA cohort, it was proven that current smokers had less chance to achieve a good European 
league against rheumatism (EULAR) response in comparison with never smokers [independent 
of Anti-citrullinated peptide antibodies (ACPA)status](36). The reasons to encourage rheumatic 
patients to drop out smoking are numerous, including to have less adverse effects along the 
treatment, less cardiovascular co-morbidities and the likelihood of a good response to DMARDs 
and TNFi(36).  
In the British registry, it has been reported that seropositive [positive rheumatoid factor 
(RF) or ACPA] RA patients present a lower clinical improvement (measured by delta-DAS28) 
than seronegative RA patients(37). Nevertheless, contradicting studies later emerged regarding 
serotype and clinical response(38). In a recent meta-analysis including more than 5000 RA 
patients, an overall lack of an interaction between serotype and outcome with TNFi is shown. On 
the other hand, a higher likelihood of achieving EULAR response in seropositive patients has 
been described with another biopharmaceutical, such as Rtx(38). In the ACTION trial, non-
responding RA patients under TNFi who started Aba treatment showed that ACPA positive RA 
patients have a higher likelihood to reach the good EULAR response and a better retention on 
the therapy(39).  
In several clinical trials, TNFi have demonstrated an enhanced effect when given in 
combination with immunosuppressive drugs like methotrexate (MTX)(40–43). The CONCERTO 
study regarding early DMARD-naïve RA patients proposes that a minimum MTX dose of 10 mg 
weekly should be co-prescribed with Ada to achieve a good clinical response(40). In contrast, no 
enhanced effect on efficacy was found in PsA when Etn in combination with DMARDs was 
compared with Etn under monotherapy(28). For other biologics such as Rtx or Aba in RA 
patients, the superiority of the combinations with MTX over monotherapy to reach a better 
clinical evolution has been proven(28). However, the concomitant therapy with MTX versus 
monotherapy does not seem to be more effective in RA patients treated with Toci(28). 
The association between TNFi serum trough drug levels and clinical outcomes will be 
discussed later with more detail. Nevertheless, it is important to highlight that many factors can 
influence trough levels, including adherence to treatment, BMI, co-prescription of DMARDs and 
the formation of anti-drug antibodies(28). A high BMI was the strongest predictor of low drug 
levels in a prospective RA cohort treated with Ada or Etn(44). The effect of the co-therapy with 
MTX on drug levels and anti-drug antibodies (ADA) detection has been described in several 
publications in rheumatic patients(25,45–50). In addition, the dose-dependent effect of MTX in 
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preventing the ADA appearance in RA and PsA patients treated with Ada has been 
described(46,50).  
 
 
Immunogenicity of tumor necrosis factor inhibitors  
 
Immunogenicity refers to antibody formation against a certain drug and all biological 
drugs can induce an unwanted immune response, mainly depending on its constitution(49,51–
58). The immune response against native biologics like human hormones, growth factors and 
cytokines occurs only when the natural tolerance is broken and differs from the immune 
response against designed biologics containing new foreign epitopes(54,56,58). Chimerical 
drugs have a higher capacity of inducing immunogenicity as compared to humanized and to 
completely human drugs(53,54,56). Immunogenicity of fusion proteins depends on their 
similarity to native proteins and Etn seems to have a less immunogenic structure compared with 
the other TNFi agents(54,56) 
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The first antibodies used in the treatment of human disease were of mouse origin, but 
most patients produced human antimouse antibodies (HAMA)(56). Immunogenicity of these 
antibodies was subsequently reduced by replacing murine constant regions with human ones, 
resulting in chimeric antibodies such as Ifx and Rtx, but they also show to induce the formation 
of human antichimeric antibodies (HACAs)(56,57). Humanization of the variable regions, like in 
Certo or Tcz, and the latter introduction of totally human antibodies further reduced 
immunogenicity, however, even fully human antibodies, like Ada and Goli, may induce the 
production of human antihuman antibodies (HAHA) which resembles the formation of anti-
idiotypic antibodies to unique determinants in endogenous antibodies which is characteristic of 
the natural immune network(56). All of these antibodies are currently denominated anti-drug 
antibodies (ADA). The fusion part of some biopharmaceuticals may contain new epitopes that 
can be recognized as foreign by the immune system. Etn is a dimeric fusion protein consisting of 
two molecules of the TNF receptor 2, linked to the Fc portion of an IgG1 and has a less 
immunogenic structure compared with the other TNF-blocking agents(56). Only the fusion part 
of the molecule can contain immunogenic epitopes and the active portion of the protein, as part 
of a natural biological receptor, is seldom the origin of an immune response(56).  
 
 
 
It has been published that the consequence of the ADA development is the alteration in 
pharmacokinetics(18,21–23,25,27,49,54,59). The ordinary half-life of IgG1 is around 3 weeks. 
Immune complexes clear faster from circulation(49,56,60). Over the last years, several reports 
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have shown that in the presence of ADA, biological drug serum levels are importantly reduced, 
suggesting the neutralization of the drug resulting from the immune-complexes 
formation(49,54,58,61–63) (Figure 5). ADA can form multivalent immune complexes with the 
target drug, leading to rapid clearance and/or inactivation of the drug, thus requiring dosage 
escalation or concomitant therapy with another agent(54,62,64,65). Rapid clearance of immune 
complexes may occur regardless of whether the antidrug antibodies neutralize the TNF-binding 
activity of the drug or not(54,62,64). 
 
 
 
Two different types of ADA have been described. Some studies show that at least some 
infliximab-specific ADA have neutralizing capacity(66). The dutch group has shown that at least 
98% of adalimumab-specific ADA are capable of neutralizing this agent, however, binding of 
both neutralizing and non-neutralizing ADA to the therapeutic agent can result in the formation 
of immune complexes, which are then cleared from the circulation, reducing the drug’s half-
life(62). The effect of neutralizing or binding ADA on the clinical response to anti-TNF agents is 
dependent on the type of therapeutic agent(62,67).  
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Nevertheless, the prevalence of ADA varies considerably in the different studies and this 
makes results lowly reliable for some clinicians(10,47,55,64,68–89) (Table 1). This observation 
can be explained by the differences between the groups of patients, as well as the differences in 
concurrent medications, timing of sampling, duration of follow-up, drug dosing and methods. 
Furthermore, the choice of the assay used for ADA detection between the radioimmunoassay 
(RIA), enzyme-linked immosorbent assay (ELISA), homogeneus mobility shift assay (HMSA) 
or reporter gene assay (RGA) or pH-shift-anti-Idiotype Antigen binding test (PIA) greatly 
influences the results(61,63,64,90–92).  
  
Association between drug and ADA levels with the clinical 
response 
 
Several publications have emerged in the last years regarding the association between 
serum trough drug and ADA levels with the clinical response in rheumatic patients. Many of 
them have demonstrated that lower serum trough levels and ADA detection are associated with a 
poorer clinical response (47,68–73,76,93,83,94). 
Fifty one consecutive RA patients treated with Ifx with a follow-up of 1 year were 
selected to study ADA status and its correlation with clinical outcomes(93). Antibodies against 
Ifx were detected in 22 patients (43%). Patients without detectable ATI (n = 29 [57%]) were 
significantly more often classified as responders (20 of 29 [69%]) compared to patients with 
detectable ATI (8 of 22 [36%]; p= 0.04)(93).  
In a long term study (after 3 years) conducted with 272 RA patients treated with Ada, 
28% of patients were ADA positive (ADA+)(47). The ADA negative (ADA-) group of patients 
had much higher serum trough Ada concentrations (median, 12 mg/L; IQR, 9-16 mg/L) 
compared to patients with antibody titers from 13 to 100 AU/mL (median, 5 mg/L; IQR, 3-9 
mg/L) and also those higher than 100 AU/mL (median, 0 mg/L; IQR, 0-3 mg/L)(47). ADA+ 
patients more often discontinued participation due to treatment failure (38%) compared with 
ADA- ones (14%). Ninety-five of 196 ADA- patients (48%) had minimal disease activity versus 
10 of 76 ADA+ patients (13%). Only 3 of 76 ADA+ patients (4%) achieved sustained remission 
compared to 67 of 196 (34%) ADA- ones(47). 
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In a study regarding a cohort of 292 RA patients treated with Etn, it was shown that Etn 
levels were significantly higher in good responders (median (IQR) 3.78 (2.53–5.17)) compared 
to both moderate 3.10 (2.12–4.47) and EULAR non-responders 2.80 (1.27– 3.93) (all p<0.05) 
after 6 months of therapy(95). When patients were categorized into quartiles according to the 
highest of Etn levels, the lowest quartile (Etn levels <2.1 mg/l) comprised 40% of all non-
responders. The highest quartile (Etn levels >4.7 mg/l) comprised 35% of all good EULAR 
responders. Anti-Etn antibodies were detected in none of the sera(95). 
De Vries et al. observed in a group of 38 SpA under Ifx therapy that serum trough Ifx 
levels were significantly (p= 0.0001) lower in ADA+ patients (mean: 0.02 mg/l) than in ADA- 
patients (mean: 12.7mg/l). Non responders by the Assessment in Ankylosing Spondylitis 
response criteria (ASAS-20) were more frequently in ADA+ patients (p=0.04) (68).  
The correlation between immunogenicity and clinical response was also studied in an 
observational study with 115 SpA treated with Ada during 24 weeks(76). At the end of the study, 
49 (43%) patients were Bath Ankylosing Spondylitis Disease Activity Index-50 (BASDAI50) 
responders and mean (SD) of Ankylosing Spondylitis Disease Activity Score (ASDAS) for 
responders was 1.5 (1.0) vs 2.6 (1.0) for non-responders (p<0.001)(76). Thirty-one (27.0%) 
patients had detectable ADA. After 24 weeks, serum trough levels (mg/L) (IQR) were 
significantly higher in ADA- patients than in ADA+ patients (12.7 (8.2–18.0) vs 1.2 (0.0–2.0), 
(p<0.001)). A significant association was demonstrated between serum trough Ada levels and 
ASDAS (p=0.02; RC −1.1; 95% CI −2.0 to −0.2). Eleven (9.6%) patients had no detectable Ada 
levels and high detectable ADA titres (>100 AU/mL). In these patients, C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR) remained high during treatment(76). 
In the present study, we have studied the association between serum trough Ifx and 
antibodies to Ifx (ATI) levels and long-term clinical outcomes (more than 4 years) in two 
Spanish cohorts of RA and SpA patients(73,96). Our group was the first to show this correlation 
during such a broad follow up time. This association has also been analyzed with surrogate 
markers of clinical response, as well as the treatment survival. 
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Another very new aspect investigated in this work is the reason to why not all 
ATI+ patients have a bad clinical course(103). When evidence is reviewed, some ATI+ 
patients present a moderate clinical response and it is not clear which differences in the 
subgroup of ATI+ patients may be the reason for this clinical variability. This question 
is partially answered in one of our articles.  
 
Association between immunogenicity and concomitant 
therapy with methotrexate (MTX) 
 
Maini et al. first investigated whether MTX could reduce the immunogenicity of 
Ifx in RA patients. In this multicenter trial, 101 RA patients were randomized into seven 
groups of 10-15 patients each, given alone or in combination with MTX, with different 
Ifx dosing regimen. The detection of ATI was inversely associated with Ifx dose (53%, 
21% and 7% in patients receiving 1, 3, 10 mg/kg monotherapy, respectively) and the 
concomitant use of 7.5 mg weekly of MTX greatly decreased the ATI detection(5).  
In a study of RA patients treated with Ifx it was shown that after 6 months of 
treatment, ADA+ patients receiving MTX had lower ADA levels than those not 
receiving MTX(104). Concomitant use of other DMARDs such as sulphasalazine 
(SSZ), ciclosporin, hydroxycloroquine (HDQ) or prednisolone did not significantly 
affect ADA levels(104).  
Similar findings have been confirmed in RA patients treated with Ada. In a 
propective RA cohort under Ada treatment over 28 weeks, the concomitant use of MTX 
was related to a lower rate of antibody development than patients with Ada under 
monotherapy (12% vs. 38%) (78).  
The relationship between immunogenicity and MTX was further explored by 
Krieckaert et al. in the same group of patients, who demonstrated a clear dose-
dependent relationship with MTX and the proportion of ADA+ patients(105). RA 
patients (n=272) under Ada treatment were stratified according to the baseline MTX 
dose: no concomitant MTX, low dose (5-10 mg weekly), intermediate dose (12.5-20 mg 
weekly) or high dose (≥22.5 mg weekly)(50). In general, patients using MTX less often 
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developed ADA compared to patients who were under monotherapy with TNFi (OR: 
0.20, 95% CI: 0.12-0.34; p=0.001). The proportion of ADA+ patients inversely 
correlated with the MTX dose(50). The group with high dose of MTX contained the 
lowest proportion of patients developing immunogenicity(50) (Figure 6). 
 
 
 
 
 
The use of MTX has also been associated with a lower incidence of ADA to 
Goli in PsA (106) and AS(107) in the context of clinical trials. The GO-REVEAL trial 
of Goli in PsA reported a low incidence of ADA (4.6% at 6 months), however, these 
were present in none patients taking concomitant MTX. The efficacy of MTX use in 
conjunction with Ifx has previously been evaluated in AS outside the context of 
immunogenicity with conflicting results(48,108). An open label study with 19 AS 
patients assessed whether the addition of MTX could increase the therapeutic efficacy at 
30 weeks(109). The 9 patients who were on low dose of MTX (7.5 mg weekly) 
achieved a significant better BASDAI50 compared with patients under 
monotherapy(109). Nevertheless, it should be taken into account that patients with 
combination treatment were younger and had shorter disease duration(109).  
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An interesting recent study conducted in PsA (n=103) and RA patients (n=272) 
evaluated the influence of MTX and other DMARDs on the serum Ada 
concentration(46). Authors concluded that Ada trough concentrations are the highest in 
patients taking MTX, with or without other DMARDs; and that patients under Ada 
monotherapy have the lowest concentrations(46). Although MTX has the strongest 
influence on Ada trough concentrations in this study, other DMARDs also seem to have 
a beneficial effect on drug levels(46).  
In relation to this issue we provide information on the relevance of concomitant 
MTX use with TNFi like Ifx in a Spanish cohort of RA and SpA patients(73,96). A 
possible interpretation would be that the combination strategy not only influences ATI 
levels, but also drug survival(73,96).  
 
Association between immunogenicity and adverse events 
 
Patients who develop antibodies to biologics are more likely to show infusion-
related reactions(72,73,104,110–113). Acute infusion reactions, including anaphylaxis, 
develop in a close temporal relationship to an infusion(110,111). The acute reactions 
can be truly allergic, namely IgE-mediated type I reactions, including hypotension, 
bronchospasm, laryngeal or pharyngeal edema, wheezing and/or urticaria. In patients 
with Crohn’s disease an increased risk of infusion reactions was observed in patients 
with higher ATI levels (49,114). In a small study using radio labeled Ifx it was 
demonstrated that in addition to the quantity of ATI, the quality of the response is 
related to infusion reactions(49). Many of the ATI are of the IgG4 and IgG1 
isotype(49,115). IgG4 antibodies are considered to be less inflammatory as they do not 
activate the complement system. In a study of 19 patients with infusion reactions to Ifx 
an association with the level of ATI was indeed observed. However, no protective effect 
of specific IgG4 was found (49). In patients who receive biological subcutaneously 
local injection reactions are frequently seen; the relation to antibody formation is, 
however, unclear. In some patients treated subcutaneously with biologics a systemic 
response is observed(116), but little information is available on the clinical effects of 
chronic immune-complex formation in these patients. In patients receiving Rtx, 
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immunogenicity has been linked to a delayed type of hypersensivity reaction with 
purpura that mimics a vasculitis-like syndrome(117). 
Ducourau et al. observed in a study in RA and SpA patients under Ifx that 52% 
(n=11) of ATI+ patients developed at least one infusion-related reaction in comparison 
with only 1 (1%) ATI-patients(71). The median interval between ATI detection and 
reactions was 42 days. These infusion reactions include rashes, hyperthermia, chills, 
Quincke´s oiedema and tachycardia. Among the 11 ATI+ patients who had an infusion 
related reaction, 4 required intra-venous corticosteroids and antihistamine, and 2 
required only per oral antihistamine. One patient developed Guillain Barré syndrome, 
which partially improved after polyvalent immunoglobulin treatment. In 4 cases, no 
treatment was required(71).  
Few detailed publications are available to explain the relationship between 
infusions related reactions, ADA development and TNFi in rheumatic patients. In the 
presented study, we have published our experience about infusion related reaction in our 
patients treated with Ifx in the Biologic Unit of the La Paz University Hospital. Besides, 
information about ATI levels and the frequency of infusion related reactions is 
provided, as well as its correlation with MTX taking(96,118).  
 
Clinical repercussion of early drug levels monitoring 
 
Since 2006, Bendtzen et al. have found that low Ifx levels at 1.5 months 
predicted antibody development and later treatment failure in a cohort of 106 RA 
patients under Ifx therapy(104). In addition, they concluded that high baseline disease 
activity, judged by CRP levels and Disease Activity Score-28 (DAS28), related to low 
Ifx levels at early stages of therapy and subsequent development of ATI(104).  
In a prospective cohort of 331 RA patients under TNFi (160 treated with Ada 
and 171 with Etn), ADA were detected in 25% of patients under Ada treatment and in 
none patients under Etn treatment. At 3 months, ADA formation and low Ada levels 
were significant predictors of no EULAR response at 12 months(44). Similar findings 
were shown from a French group in a pilot study with a reduced number of patients 
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treated with Etn. They observed that Etn concentrations at 3 months predict response to 
Etn therapy at 6 months, but no data about survival of the drug were provided(119). 
Low Etn concentrations could explain low levels of response as suggested 
previously(119).  
In relation to Ifx at early stages, Ducourau et al. have shown in a RA and SpA 
cohort under Ifx that trough Ifx concentration during treatment initiation (weeks 2 and 
14) was lower for ATI+ than ATI- patients and the difference was as early as week 
2(71) (Figure 7). Another group has also described the association of early drug levels 
and clinical activity to predict clinical outcomes. Kobayashi et al. observed in a cohort 
of ulcerative colitis (UC) that early Ifx levels at week 2 in combination with clinical 
evaluation, is useful to predict short-long-term outcomes(120).There is sparse evidence 
available about biologic drug levels at early stages in rheumatic diseases. A Dutch 
group showed in a 57 RA patients treated with Ifx that the combination of DAS28 at 
week 6 of therapy with Ifx trough levels could be predictors of clinical response at 6 
months(121).  
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In our cohort of RA patients, we have obtained very novel and interesting data 
on this topic. Firstly, the early Ifx levels (at weeks 2, 6 and 14) have been correlated 
with clinical outcomes during the first year of therapy (article 4). Furthermore, we have 
defined a serum level cut-off at early stages of treatment to predict ATI status and 
clinical response during the first year under Ifx therapy (article 4). Moreover, this study 
has demonstrated that the differences in drug levels at early stages are partly 
conditioned by an early ATI production detected with immune-complex dissociation 
assays (article 4).  
 
Therapeutic drug monitoring (TDM) strategies 
 
In the absence of response to a first TNFi, different strategies, some of them 
proposing drug levels as the main predictor of response are routinely used, such as a 
change in the current TNF inhibitor dose, shortening infusion intervals (notably for Ifx), 
switching to another TNFi or switching to a drug with a different mechanism of 
action(122). There is at present no accepted rationale for the approach to primary and 
secondary failure of TNFi, and this means an important issue from both a clinical and 
economic perspective. The Dutch group has proposed that measurement of ADA before 
switching may be of value in clinical decision making(87,123). In RA, anti-TNF naive 
patients and switchers with ADA against their first TNFi showed similar responses to a 
second TNFi which were superior to the responses of switchers without detectable 
ADA(87,123) This suggests that TNFi failures in the absence of ADA may have a 
target-related reason for anti-TNF failure, and thus be better suited to a drug with a 
different mechanism of action, whilst those with ADA may have a drug-related failure.  
For many biologics, mainly Ifx, increasing the dose has been proposed in 
patients with primary or secondary failure(124–126). Some studies have shown that 
therapeutic intensification significantly improves responses(124), whereas other showed 
little or no effect(125,126). Most of these studies did not monitor serum drug 
concentration or ADA. It is important to define if this intensification therapy regimen is 
effective in order to prevent toxicity and high costs. We know that the answer to these 
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questions will be provided with a prospective study but we will report our preliminary 
data in an observational cohort and these results can help to run a clinical trial. 
Many algorithms have been proposed to implement the use of serum trough drug 
and ADA levels in clinical practise(18,127–130) (Figure 8). Most of these algorithms 
combine clinical outcomes with drug and/or ADA status. Garcés et al. proposed a new 
algorithm considering ADA status and clinical response and compared the concordance 
of this algorithm with the current clinical practise comparing the effectiveness of 
“immunogenicity-based” versus “empirical-based” switches in a cohort of RA patients 
receiving biologics(127). Finally, it was observed that the “immunogenicity-based” 
group had more probability to achieve clinical response than the other group(127). 
Currently, more studies are emerging to reinforce the incorporation of drug/ADA levels 
monitoring as a tool in the clinical evaluation of the rheumatic patients. This process is 
known as TDM.  
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In the last year, it is becoming more common to reduce the dose and/or increase 
the administration interval of biologics (tapering strategies) in patients with sustained 
low disease activity or remission. This attitude is for purposes of avoiding overtreatment 
in patients with long-standing exposition to biologics, decreasing the risk of infections 
or adverse events and using cost-effective strategies. Although there is increasing 
evidence that the tapering strategy is feasible in some patients clinicians are concerned 
about long-term clinical or structural consequences(125,131–140).  
In the present work, we will provide an exhaustive review about the current 
situation regarding tapering strategies or discontinuation of biologics in axial SpA 
patients. Moreover, two interesting studies comparing long-term clinical outcomes 
between patients under a biologic tapering strategy versus patients with standard 
therapy regimen will be presented. For these studies, short and long-term clinical 
outcomes were collected, including the incidence and number of flares in both 
populations: the tapering group and the control group (with standard dose regimen). 
Besides, data demonstrating that TDM use in our cohort of rheumatic patients under 
biologics is a cost-effective strategy will be shown. 
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Our hypothesis were: 
 
I. A faster TNFi clearance and ADA formation are associated with a poorer 
clinical response in rheumatic patients.  
 
II. The concomitant therapy with immunosuppressive as MTX has an influence on 
the serum trough drug and ADA levels in rheumatic patients under TNFi.  
 
III. Patients under Ifx therapy who develop ADA present lower Ifx levels since the 
induction phase of treatment. 
 
IV. The development of ADA against to the first TNFi may determine the clinical 
response to a second TNFi.  
 
V. Increasing dose of biological drugs is not an effective long-term therapeutic 
strategy 
 
VI. A biologic tapering strategy is feasible in rheumatic patients in low disease 
activity or remission with a good control of the disease and important reduction 
of the administered drug.  
 
VII. The economic impact of the biological therapy optimization in patients with 
chronic inflammatory diseases by monitoring the drug and ADA levels is 
remarkable.
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The main objectives of this study are: 
 
I. To analyze the clinical relevance of the detection of ADA in RA and SpA 
patients under biological drugs. Several aspects will be evaluated: effect of 
concomitant MTX use, incidence of adverse event, timing of ADA appearance, 
influencing on the switching to a second TNFi. 
 
II. To analyze whether patients who develop ADA present differences on serum 
drug levels since the induction phase.  
 
III. To analyze the relationship between serum drug levels and the clinical response 
to the treatment with biological drugs. This will be done with different 
biopharmaceuticals as Ifx, Tcz, and Goli.  
 
IV. To analyze the effect of the TDM on the treatment: effect of drug increase, TNFi 
discontinuation, tapering in patients with low disease activity or remission, 
consequences on cost-effectiveness. 
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Global Summary 
 
Chapter 1: 
Association between drug and ADA levels with clinical outcomes 
 
ARTICLE 1: “Influence of immunogenicity on the efficacy of long-term 
treatment with infliximab in rheumatoid arthritis” (72) 
 
In this study 85 RA patients from RA-Paz cohort under Ifx treatment were 
included. Clinical activity, response and serum trough Ifx and ATI levels were 
measured at baseline, 6 months, 1 year and more than 4 years of treatment.  
ATI were detected in 28 (33%) patients along the study. At baseline no 
significant differences in clinical activity between ATI+ versus ATI- patients were 
found. ATI+ patients showed a higher clinical activity measured by DAS28 at all 
studied point (6 months: 4.85±1.24 ATI+ vs 3.67±1.24 ATI-, p=0.004; 1 year: 
4.95±1.24 ATI+ vs 3.13±1.17 ATI-, p=0.004; >4 years: 4.00±1.35 ATI+ vs 3.46±1.22 
ATI-, p=0.004). At the end of the study, 100% of EULAR non responders were ATI+ 
patients and only the 24% of EULAR (good and moderate) responders were ATI+.  
Ifx trough levels were higher in EULAR responders; however, ATI levels were 
significantly higher in EULAR non responders at all studied point (Figure 9). 
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Forty five (54%) patients discontinued Ifx therapy and this proportion was higher in 
ATI+ patients (23/28 (82.1%) ATI+ patients vs 22/57 (39%) ATI- patients, p<0.001). 
Among ATI+ patients, Ifx survival was longer in patients taking concomitant therapy 
(p=0.022) (Figure 10). 
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Infusion related reactions appeared in 9 patients, all of them with detectable 
ATI. Among the 28 ATI+ patients, ATI levels were higher in the group with infusion 
related reactions (Figure 11).  
 
 
 
We did not find a lower proportion of patients developing ATI in association 
with MTX use (32% with MTX vs 37% without MTX, p=0.77). However, in ATI+ 
patients receiving MTX, maximal levels (Mdn-IQR) tended to be lower than in those 
ATI+ patients without MTX (3414, 808-7426 AU/ml with MTX vs 21250, 7049-47656 
AU/ml without MTX, p=0.07).  
 
 
ARTICLE 2: “Influence of immunogenicity on the efficacy of long-term treatment of 
spondyloarthritis with infliximab” (73) 
 
Ninety four axial SpA from SpA-Paz cohort treated with Ifx were included in 
this study. Clinical activity and serological parameters were measured at baseline, 6 
months, 1 year and >4 years of treatment.  
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ATI were detected in 24 (26%) patients, in 71% of them within the first year of 
therapy. ATI+ patients had a more active disease by ASDAS than ATI- patients at all 
studied time point ((6 months: 2.55±0.89 ATI+ vs 1.79±1.04 ATI-, p=0.038; 1 year: 
1.95±0.67 ATI+ vs 1.67±0.71 ATI-, p=0.042; >4 years: 2.52±0.99 ATI+ vs 1.53±0.81 
ATI-, p=0.004). During the study, 51 (54%) patients had a clinically significant 
improvement and only 9 of them were ATI+ (p=0.047). Ifx trough levels were higher in 
inactive patients at any studied point (Figure 12). 
 
Twenty seven (29%) patients dropped out Ifx during the study, most of them 
ATI+ patients (18/24 (75%) ATI+ versus 9/70 (13%) ATI-, p>0.001).  
Infusion related reactions were seen in 11 SpA patients, the majority of them in 
the ATI+ patients (73% ATI+ vs 27% ATI-, p=0.001). Moreover, ATI levels were 
higher in the patients who developed an infusion related reaction (p=0.028) (Figure 13). 
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ATI were detected more frequently in patients not taking MTX than in patients 
with concomitant MTX (20/58 (35%) without MTX versus 4/36 (11%) with MTX, 
p=0.011). Moreover, the maximum Ifx levels (mean ±SD) tended to be higher in 
patients taking concomitant MTX than patients with biological drug in monotherapy 
(4548 ±3832 with MTX vs 3485 ±3018 without MTX, p=0.147). 
 
ARTICLE 3: “The timing of serum infliximab lose, or the appearance of antibodies 
to infliximab (ATI) is related with the clinical activity in ATI-positive patients with 
rheumatoid arthritis” (103) 
 
To understand the reason why not all ATI+ patients have a poor clinical 
response, we investigated whether the timing of ATI appearance and/or drug 
disappearance is correlated with clinical activity, measuring the Ifx and ATI levels 4 
weeks after infusion (n+4).  
Eleven ATI positive RA patients were included in this study. Patients who had 
detectable ATI four weeks earlier (half cycle) showed higher disease activity measured 
by DAS28 (6.56±0.69 ATI+ at half cycle vs 4.56±0.93 ATI- at half cycle, p=0.012) and 
worse clinical improvement measured by delta-DAS28 (-1.22±0.72 ATI+ at half cycle 
vs 0.94±0.93 ATI- at half cycle, p=0.012) at the study point (Figure 14). Moreover, ATI 
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levels were higher in ATI+ patients at half cycle (Mdn, IQR: 8038 (2640-12063) ATI+ 
at half cycle vs 260 (131-342) ATI+ at half cycle p=0.024).  
 
 
ARTICLE 4: “Predictive Value of Serum Infliximab Levels at Induction 
Phase in Rheumatoid Arthritis Patients” 
 
This is an observational study in which Ifx trough levels (ITL) from 66 RA 
patients were measured by ELISA at week (W) 0, W2, W6, W14 and W22. Patients 
were classified as ITLpos if Ifx was detectable at W54 and ITLneg otherwise. ATI were 
assayed by bridging ELISA and by two drug-tolerant assays. ITL cut-off values were 
established by receiver operating characteristic (ROC) curves.  
The ITLneg patients at W54 had lower early-stage ITL than the ITLpos patients 
(W2: 20.0 ±12.7 µg/mL vs 29.7±14.5 µg/mL (p=0.015); W6: 4.2±5.9 µg/mL vs 
15.7±11.1 µg/mL (p<0.0001); W14: 0.1±0.2 µg/mL vs 4.1±5.3 µg/mL (p<0.0001); and 
W22: 0.01±0.04 µg/mL vs 2.8±3.3 µg/mL (p<0.0001)) (Figure 15). At all studied time 
points, the areas under the curve (AUC) of the ROC curves were statistically different 
from 0.5, enabling cut-off levels to distinguish between ITLpos and ITLneg patients at 
W54. The W6 predictive cut-off (4.4 μg/mL) showed the best association with IFX 
absence at W54, with a sensitivity of 70% (95% confidence interval (CI): 45.7-88.1), a 
specificity of 95% (95% CI: 83.1-99.4) and a positive likelihood ratio of 14 (Figure 16). 
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Therefore, the W6 predictive cut-off was considered the reference value to predict 
clinical and serological outcomes for further analysis.  
In the univariable analysis, three factors were significantly associated with Ifx 
absence at W54: i) having an ITL below the cut-off at W2 (odds ratio (OR): 12.40; 95% 
CI: 3.48-44.15) or at W6 (OR: 44.33; 95% CI: 7.99-246.03), ii) non-use of MTX (OR: 
4.20; 95% CI: 1.33-13.32) and iii) being older (OR: 1.04; 95% CI: 1.03-1.07). 
In the multivariable logistic regression analysis, even after adjusting for possible 
confounders (age, gender and baseline DAS28), the ITL below the cut-off at W2 (OR: 
15.85; 95% CI: 2.95-85.03; p=0.01) or at W6 (OR: 86.64; 95% CI: 6.58-1139.99) and 
also the non-use of MTX (OR: 12.26; 95% CI: 1.83-82.22) remained significantly 
associated with Ifx absence at W54. 
 
 
Patients with ITL above the W6 predictive cut-off (4.4 µg/ml) had lower DAS28 
scores at W54 than patients with ITL below the cut-off (3.68±1.26 vs 4.75±1.27; 
p=0.01). Most patients with low disease activity or remission by DAS28 at W54 had 
ITL above predictive cut-off at W6 (ITL above: 20 of 45 patients (44%) vs ITL below: 
3 of 19 patients (16%); p=0.02).  
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ARTICLE 5: “Serum Tocilizumab trough concentration can be used to monitor 
systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective 
observational cohort study” (85) 
 
This study included 66 RA patients (34 patients from the Netherlands and 32 
patients from Spain). Clinical parameters were collected at baseline, 4, 12 and 24 weeks 
in the Dutch cohort and at baseline and 24 weeks of treatment in the Spanish cohort. 
Serum trough levels were measured at baseline, 4, 12 and 24 weeks in both cohorts.  
In total, nine patients had Tcz levels <1mg/L in 2 subsequent visits. Only 1 out 
of the 3 patients with low Tcz levels had detectable ADA.  
Tcz concentration above 1 mg/L was sufficient to normalize the serum CRP 
levels (≤10 mg/L). Spearman´s rank correlation coefficient showed a significant 
negative correlation between Tcz and CRP levels (-0.460, p<0.001). 
Twelve patients (18%) did not achieve a significant improvement by delta-
DAS28 at 24 weeks (delta-DAS≥1.2) and the 67% (8/12) of them had Tcz concentration 
<1mg/L. A linear regression coefficient of 0.080 (95% CI: 0.039-0.113, p<0.001) for 
the association between Tcz concentration and delta-DAS28 at 24 weeks was found.  
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ARTICLE 6: “Golimumab trough levels, antidrug antibodies and clinical response in 
patients with rheumatoid arthritis treated in daily clinical practice” (102) 
 
This prospective observational study included 37 RA patients treated with Goli 
at standard therapy regiment (50 mg sc monthly), recruited from the Spanish cohort of 
La Paz-Spain and from the Dutch cohort of Reade Centrum-the Netherlands.  
At week 52, 15 patients (41%) were responders and 22 (59%) non-responders by 
DAS28. The 51% (19) of patients dropped out Goli during the first year of therapy (11 
for inefficacy, 7 for side effects and 1 for other reasons).  
The median of Goli levels measured in serum was significantly higher in 
responders compared with non responders (1.36, 0.5-1.82 in responders versus 0.43, 
0.23-0.84 in non-responders, p=0.023). 
All patients were stratified according to Goli levels into quartiles. The lowest 
quartile comprised the 32% of non-responders in comparison with the higher quartile 
that comprised the 47% of responders (Figure 17).  
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Chapter 2: 
Therapeutic strategies based on monitoring of drug and ADA levels 
 
ARTICLE 7: “The immunogenicity to the first anti-TNF therapy determines the 
outcome of switching to a second anti-TNF therapy in Spondyloarthritis patients” 
(118) 
 
Forty two SpA patients from SpA-Paz cohort were enrolled in this study. All 42 
SpA patients received a first TNFi (20 with Ifx, 5 with Ada and 17 with Etn) and were 
switched to a second TNFi (9 with Ifx, 19 with Ada, 8 with Etn and 6 with Goli). 
Immunogenicity status against the first TNFi was analyzed before switching and clinical 
response to second TNFi (based on ADA pos/neg status during the 1
st
 TNFi) was 
studied at 6 months of switching by ASDAS.  
ADA were detected in 11 (26%) patients and appeared mainly within the first 
year of TNFi therapy. Most ADA negative patients against to the first TNFi had clinical 
inefficacy and detectable drug levels just before switching.  
At 6 months after switching, ADA positive SpA patients against to the first 
TNFi had a lower clinical activity measured by ASDAS in comparison with ADA 
negative patients (1.62±0.93 ADA pos vs 2.79±1.01 ADA neg, p=0.002).  
After 6 months of switching, most ADA neg against the first TNFi patients were 
classified as being in high or very high disease activity by ASDAS (81% ADA neg vs 
27% ADA pos, p=0.002) (Figure 18).  
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ARTICLE 8: “Effect of infliximab dose increase in rheumatoid arthritis at different 
trough concentrations: a cohort study in clinical practice conditions” (141) 
 
A retrospective observational study, including 42 RA patients treated with Ifx 
from RA-Paz cohort, was carried out to analyze the effect of Ifx dose escalation 
strategies on clinical activity. Clinical and serological parameters were studied before 
dose increase (T1), 1
st
 visit after dose increase (T2), 6 months after dose increase (T3) 
and 12 months after dose increase (T4). Patients were classified based on Ifx/ADA 
status before dose increase: group 1 with 20 without Ifx levels (ADA pos), group 2 with 
13 with low Ifx levels and group 3 with 9 with high Ifx levels.  
Considering the total population, DAS28 improved at T2 (4.55±1.01 at T1 vs 
3.95±1.22 at T2, p<0.005) but this improvement disappeared at T4 (3.98±1.22 at T4, 
p=0.075). The delta-DAS28 demonstrated a significant worsening during the study 
(from -0.63±1.18 at T2 to 1.17±1.45 at T4, p<0.001).  
In the analysis of individual patients groups, no significant change in DAS28 
was observed throughout the study (Figure 19). Nevertheless, the decrease in disease 
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activity from T2 was significant in group 1 (1.0±1.9 at T2 vs -0.7±1.0 at T4, p<0.05) 
and group 3 (1.3±1.3 at T2 vs -1.0±1.3 at T4, p<0.05) after12 months (Figure 19).  
 
 
 
Chapter 3: 
Tapering or Discontinuation strategies in rheumatic patients 
 
ARTICLE 9: “Anti-TNF discontinuation and tapering strategies in patients with 
axial spondyloarthritis: a systemic literature review” (142) 
 
Thirteen studies out of 763 retrieved citations were included. In general, 
published data are scarce and the level of evidence of the studies is weak. Five studies 
provided evidence for assessing discontinuation and eight studies evaluating tapering 
strategy.  
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On discontinuation studies, 4 of these works were observational studies after 
participation in RCT and 1 of them was a RCT to evaluate the effect of thalidomide to 
prevent flare after TNFi discontinuation. In total, they included 220 SpA patients. In 
these studies, patients receiving standard dose of TNFi discontinued this therapy and 
were followed to assess the appearance of flare. The median (range) percentage of 
flaring patients was 79% (76-100%). In the four observational studies, patients were 
retreated with the same TNFi, achieving a good clinical response in most patients.  
Eight studies evaluated the tapering strategy of TNFi in SpA with LDA or 
remission. Dose reduction was most frequently done by increasing the interval of 
administration. The majority of patients maintained the LDA or reduction (proportion of 
patients: 53%-100%) or presented a low BASDAI (mean BASDAI: 0.6-3.2) after 
tapering strategies in the evaluated studies.  
 
ARTICLE 10: “Comparing tapering strategy to the standard dosing regimen of TNF 
inhibitors in rheumatoid patients with low disease activity” (143) 
 
Two groups of 144 RA patients on TNFi with DAS28<3.2 were compared: 
tapering group (TG: 67 patients from Spain) and control group with standard therapy 
regimen (CG: 77 patients from the Netherlands). The clinical and serological parameters 
were measured at baseline (visit 0), prior to start the tapering strategy in TG and with 
DAS28<3.2 in TG and CG at least 6 months (visit 1), 6 months after visit 1 (visit 2), 1 
year after visit 1 (visit 3), the last visit available after visit 1 (visit 4) and the visit with 
the worst flare between visit 1 and visit 4 (visit-flare). In the TG, 23 patients were 
treated with Ifx, 23 with Ada and 21 with Etn. In the CG, 22 patients received Ifx, 27 
Ada and 28 Etn.  
The clinical course measured by DAS28 was similar in both groups during the 
study (Figure 20). A similar behavior was observed in the analysis between the 
different TNFi. 
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Fifty six (39%) RA patients had a flare throughout the study without significant 
differences between groups (39% in TG vs 39% in CG, p=0.324). Also, no differences 
were observed between the number of flares (1.8±0.8 in TG vs 1.7±0.7 in CG, p=0.575) 
or the time to appear the first flare between both groups (1.3±0.8 years in TG vs 1.4±0.7 
years in CG, p=0.580).  
In the TG, a significant reduction in the drug levels was observed between visit 1 
and visit 4 (p≤0.001). Fourteen percent of patients were ADA positive at the end of the 
study and most of them were in the TG (20% ADA pos in TG vs 9% ADA pos in CG, 
p=0.052).  
The time in low disease activity prior to start the tapering strategy (OR: 0.35; 
95% CI: 0.13-0.9) was the only predictive factor that demonstrated to be protector of 
having a flare during the follow-up.  
At the end of the study, most patients in the TG were using the therapy regiment 
according to the tapering strategy without requiring the use of standard labeled dose 
(83% in Ifx, 100 % in Ada and 86% in Etn).  
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At visit 4, an important reduction of administered drug was observed in TG in 
comparison to the CG with an interval elongation of 33% for Ifx, 53% for Ada and 53% 
for Etn.  
 
ARTICLE 11: “Comparing tapering strategy to the standard dosing regimen of TNF 
inhibitors in spondyloarthritis with low disease activity” (144) 
 
Two groups of 117 SpA patients on TNFi at least in LDA were compared: 
tapering group (TG: 74 patients from Spain) and control group with standard therapy 
regimen (CG: 43 patients from the Netherlands). The clinical and serological parameters 
were measured at baseline (visit 0), prior to start the tapering strategy in TG and with 
DAS28<3.2 in TG and CG at least 6 months (visit 1), 6 months after visit 1 (visit 2), 1 
year after visit 1 (visit 3), the last visit available after visit 1 (visit 4) and the visit with 
the worst flare between visit 1 and visit 4 (visit-flare). In the TG, 35 patients were 
treated with Ifx, 17 with Ada and 22 with Etn. In the CG, 21 patients received Ada and 
22 Etn. No CG for Ifx was available in the Dutch cohort.  
The clinical course measured by BASDAI was similar in both groups during the 
study (Figure 21). A similar behavior was observed in the analysis between the 
different TNFi. 
Thirty (26%) SpA patients experienced a flare along the study without 
significant differences between groups (30% in TG vs 19% in CG, p=0.184). Moreover, 
no differences were observed between the number of flares (1.4±0.7 in TG vs 1.5±0.5 in 
CG, p=0.486) or the time to appear the first flare between both groups (1.3±0.8 years in 
TG vs 1.3±1.2 years in CG, p=0.841).  
P 
U 
B 
L 
I 
C 
A 
T 
I 
O 
N 
S 
 Immunogenicity of biological drugs in inflammatory rheumatic diseases: clinical relevance and therapeutic drug monitoring 
 
 
70 
 
 
In the TG, a significant reduction in the drug levels was observed between visit 1 
and visit 4 (p≤0.001). Fourteen percent of patients were ADA positive at the end of the 
study, being significantly more frequent in the TG (19% ADA pos in TG vs 5% ADA 
pos in CG, p=0.028).  
To be a male (OR: 3.5; 95% CI: 1.2-10.4) was the only predictive factor that 
demonstrated to be protector of having a flare during the follow-up.  
At the end of the study, most patients in the TG were using the therapy regiment 
according to the tapering strategy without requiring the use of standard labeled dose 
(97% in Ifx, 94 % in Ada and 86% in Etn).  
Overall, the reduction of the administered drug at visit 4 in the TG was 22% for 
Ifx and the interval elongation was extended to 29%. The reduction of administered 
drug was around 45% for Ada and 52% for Etn.  
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Chapter 4: 
Economic repercussion of tapering strategies by monitoring 
drug/ADA levels (TDM) 
 
ARTICLE 12: “Dose-Tapering of TNF inhibitors in daily rheumatology practice 
enables the maintenance of clinical efficacy while improving cost-effectiveness” (145) 
 
A total of 77 rheumatic patients (36 RA and 41 SpA) under TNFi with sustained 
LDA from RA-Paz cohort were included. The same patients were studied in two 
different periods: 1
st
 period (1
st
 P) with standard therapy regimen between 2007-09 and 
a 2
nd
 period (2
nd
 P) with a tapering strategy between 2010-12. Out of 77 RA patients, 29 
were under Ifx, 27 under Ada and 21 under Etn. Clinical activity was measured by 
DAS28 for RA patients and by BASDAI for SpA patients.  
No differences were observed in the clinical activity of patients between the 1
st
 
and 2
nd
 P, even when a sub-analysis among the different TNFi was performed (Figure 
22).  
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In the 2
nd
 P, the interval of drug administration was higher for all TNFi (8.7 ± 
1.4 weeks in the 1
st
 P vs 9.85 ± 1.5 weeks in the 2
nd
 P, p<0.001 for Ifx; 2.3 ± 0.63 weeks 
in the 1
st
 P vs 3.1 ± 1.02 weeks in the 2
nd
 P, p<0.0001 for Ada; 1.4 ± 0.56 weeks in the 
1
st
 P vs 2.16 ± 1.57 weeks in the 2
nd
 P, p<0.05 for Etn). 
During the 2
nd
 P, serum trough drug levels were significantly lower. The 
mean±SD serum drug levels in the 1
st
 P versus serum drug levels in the 2
nd
 P were 3.2 ± 
2.5 μg/ml vs 1.8 ± 1.5 μg/ml (p<0.0001) for Ifx; 5.5 ± 2.8 μg/ml vs 3.1 ± 2.1 μg/ml 
(p<0.0001) for Ada; and 1.8 ± 1.1 μg/ml vs 1.3 ± 0.8 μg/ml (p<0.05) for Etn. The 
appearance of immunogenicity was not higher in the 2
nd
 P (3 patients in the 1
st
 P vs 7 
patients in the 2
nd
 P) and mean antibody levels in the 10 patients (17 samples) were very 
low (anti-Ifx antibodies: 18 ± 13 AU/ml; anti-Ada antibodies: 12 ± 8.7 AU/ml). 
The amount of drug consumed decreased by 18% for Ifx, 23% for Ada and 19% 
for Etn in the 2
nd
 P, resulting in an average saving of 20% in the amount of drug per 
year. Based on the prices of these drugs in our hospital at the end of 2012, the cost/year 
for each patient was significantly reduced in the 2
nd
 P for all three TNFi (Figure 23); the 
estimated total cost saving was approximately €153,798/year, with a mean 
saving/patient/year of €1,715 for Ifx, €2,580 for Ada, and €1,638 for Etn. 
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ARTICLE 13: “Anti-TNF dose and anti-drug antibody levels in rheumatic and 
psoriasis patients: economic repercussion” (146) 
 
This is an ambispective observational study with a retrospective period (2009-
2012) including patients without tapering strategy and a prospective period (started in 
2013) including patients under a tapering strategy.  
In total, the therapy regimen of biologic agents was checked in 449 adults with 
rheumatic diseases (209 RA and 240 SpA patients) and 167 adults with psoriasis.  
Out of 209 RA patients, 145 were in subcutaneous TNFi regimen and 64 with 
intravenous biological agent, being 26 patients on Ifx. From 2013, the 43% of RA 
patients were under a tapering strategy [46.2% (67/145) under sc biologic and 36% 
(23/64) under iv biologic].  
In the SpA group, 176 were receiving subcutaneous biologic and 64 were treated 
with intravenously Ifx. Beginning with 2013, 41% percent of SpA patients were under 
tapering strategy (39% under sc biologic and 47% under iv biologic).  
Forty eight percent of psoriasis patients were under a tapering strategy from 
2013 (38% under sc therapy and 44% under iv therapy).  
A progressive reduction in cost/patient/year, in the departments of 
Rheumatology and Dermatology, was seen along the study.  
 
 
 
 
P 
U 
B 
L 
I 
C 
A 
T 
I 
O 
N 
S 
 Immunogenicity of biological drugs in inflammatory rheumatic diseases: clinical relevance and therapeutic drug monitoring 
 
 
75 
 
Chapter 1: Association between drug and ADA levels with 
clinical outcomes 
 
ARTICLE 1: “Influence of immunogenicity on the efficacy of long-term treatment 
with infliximab in rheumatoid arthritis” 
 
ARTICLE 2: “Influence of immunogenicity on the efficacy of long-term treatment 
of spondyloarthritis with infliximab” 
 
ARTICLE 3: “The timing of serum infliximab loss or the appearance of antibodies 
to infliximab (ATI) is related with the clinical activity in ATI-positive patients with 
rheumatoid arthritis” 
 
ARTICLE 4: “Predictive Value of Serum Infliximab Levels at Induction Phase in 
Rheumatoid Arthritis Patients” 
 
ARTICLE 5: “Serum Tocilizumab trough concentration can be used to monitored 
systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective 
observational cohort study” 
 
ARTICLE 6: “Golimumab trough levels, antidrug antibodies and clinical response 
in patients with rheumatoid arthritis treated in daily clinical practice” 
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ARTICLE 1 
 
TITLE: “Influence of immunogenicity on the efficacy of long-term treatment 
with infliximab in rheumatoid arthritis”  
JOURNAL: Rheumatology 2011;50(8):1445–52(72) 
 
AUTHORS: Dora Pascual-Salcedo, Chamaida Plasencia, Susana Ramiro, 
Laura Nuño, Gema Bonilla, Daniel Nagore, Ainhoa Ruiz del Agua, Antonio Martínez, 
Lucien Aarden, Emilio Martín-Mola and Alejandro Balsa 
 
PATIENTS AND METHODS: 
Patients, sera and clinical assessment 
 
A total of 85 consecutive patients with RA treated with Ifx, without previous 
biological treatment were included, from RA-Paz cohort. This was a retrospective 
observational study, approved by the Hospital La Paz Ethics Committee and patients 
signed an informed consent. Serum samples (a total of 1451) were collected at the time 
of infusion, stored frozen and only thawed for the purpose of this study. The 
retrospective study period covers the years 1999 until 2010. All patients fulfilled the 
ACR 1987 revised criteria for RA and all of them had evidence of active disease, 
as indicated by a 28-joint DAS (DAS-28) at inclusion of 5.49 (1.2) [mean (S.D.)]. At 
first all patients were given iv infusions of 3 mg/kg Ifx at 0, 2, 6 and every 8 weeks 
thereafter. After 14 weeks of treatment, the rheumatologist was allowed to increase the 
Ifx dosage to 5 mg/kg depending on the observed clinical response. The clinical activity 
and response was measured by DAS28 and EULAR response criteria at baseline, 6 
months, 1 year and >4 years [mean (S.D.) 5.9 (2) years].  Blood samples were collected 
at baseline and just before each infusion at 2, 6 and every 8 weeks thereafter, so that a 
maximum of 6-8 samples per year were obtained from each patient.  
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Serum infliximab assay 
 
Serum Ifx levels were determined by a sandwich ELISA. Briefly, microstate 
plates were coated with 2 mg/ml mouse monoclonal anti-TNF antibody (CLB/7) 
(Sequin, Amsterdam, The Netherlands) and then incubated with 0.01 mg/ml 
recombinant human TNF-a (Partech, Rocky Hill, USA). Serial dilutions of serum 
samples and standard curve (0.1_50 nag/ml Ifx) were made in high performance ELISA 
(HPE) buffer (Sequin). Bound Ifx was detected with biotinylated affinity purified rabbit 
immunoglobulin G (IgG) to Fab regions of Ifx, and the reaction was developed with 
streptavidin-polyperoxidase (polyHRP) (Sequin). The detection limit of the assay was 1 
nag/ml infliximab. Cut-off values were established with sera from 150 healthy blood 
donors and 100 RA patients who had never received Ifx (of whom 70% were RF 
positive) to exclude any background signal that might have been caused by RF or other 
auto-antibodies present in RA patient sera. Serum Ifx levels >10 nag/ml (mean + 6 S.D. 
control group) were considered positive. 
 
Anti-infliximab Ab assay 
 
ATI were detected by a two-site (bridging) ELISA, which takes advantage of the 
monovalency of the two arms of IgG subclasses 1, 2 and 3, to crosslink the Ifx coated 
on plates to biotinylated Ifx [11, 19]. Polystyrene plates (Nunc A/S, Roskilde, 
Denmark) were coated with Ifx (0.5 mg/ml) overnight. The following day, serial 
dilutions of samples (starting at 1/10) and a standard curve (0.48_250 AU/ml) diluted in 
HPE were incubated for 1 h with shaking. A standard curve was constructed using a 
patient serum that showed a high titre ATI (mainly IgG1) previously titrated in arbitrary 
units per millilitre by one of the authors 1446 of this study (L.A., data not shown). After 
washing, 10 nag/ml Ifx biotinylated by standard procedures (Pierce, Rockford, IL, 
USA), was added. Bound labeled Ifx was detected by incubation with polyHRP (1: 10 
000) in PBS. The reaction was developed with tetramethylbenzidine (TMB)/H2O2 in 
0.11M acetic acid buffer pH = 5.5 and stopped with 2M H2SO4. Washing steps were 
made in 0.01M PBS 0.02% Tween 20. The assay detection limit was 2 AU/ml and the 
cut-off for the presence of ATI in patient sera was established at 50AU/ml (mean + 6 
S.D.) with the same control group used for the measurement of free Ifx. A linear dose-
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response curve for inhibition was obtained when positive samples for ATI were pre-
incubated with Ifx. 
 
Statistical analysis 
 
Descriptive statistics were provided using the mean, S.D., median (Mdn) and 
interquartile range (IQR). Statistical analysis was performed using the Statistical 
Package for the Social Sciences version 10.0 (SPSS, Chicago, IL, USA). Frequency 
data were compared by the Pearson’s chi-square and Fisher’s exact tests. Differences in 
quantitative values between groups were analyzed using Mann Whitney U and 
Wilcoxon non-parametric tests. Time course data were analyzed using the Kaplan Meier 
method. Statistical significance was calculated using the log-rank test and P<0.05 was 
considered statistically significant. 
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ARTICLE 2 
 
TITLE:”Influence of immunogenicity on the efficacy of long-term treatment 
of spondyloarthritis with infliximab” 
JOURNAL: Ann Rheum Dis 2012;71:1955–60(73) 
 
AUTHORS: Chamaida Plasencia, Dora Pascual-Salcedo, Laura Nuño, Gema 
Bonilla, Alejandro Villalba, Diana Peiteado, Jesús Díez, Daniel Nagore, Ainhoa Ruiz 
del Agua, Rosario Moral, Emilio Martin-Mola, Alejandro Balsa 
PATIENTS AND METHODS: 
Patients and serum samples 
 
A total of 94 patients with Spa, who had not received previous biological 
treatment, from SpA-Paz cohort were included. This was an ambispective observational 
study that was approved by the La Paz Hospital ethics committee. The patients signed 
an informed consent form. Serum samples (a total of 2116) were collected at the time of 
infusion. The retrospective study period covered the years from 1999 to 2008, and the 
prospective study period extended from 2009 to 2010. All of the patients with AS 
fulfilled the revised New York criteria. The patients with PsA fulfilled the GRAPPA 
(Group of Research and Assessment of Psoriasis and Psoriatic Arthritis) group criteria. 
All the patients with IBD fulfilled the ESSG (European Spondylarthropathy Study 
Group) criteria. At the time of inclusion, all patients had evidence of active disease, as 
indicated by their mean Ankylosing Spondylitis Disease Activity Score (ASDAS) of 
3.08 (1.31) (mean (SD). All the patients were given intravenous infusions of 5 mg/kg 
IFX at 0, 2 and 6 weeks and then every 8 weeks thereafter. Every 6 months, disease 
activity was measured using the ASDAS (in the retrospective group of patients, the 
clinical response data were extrapolated from the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI)).23 Six months, 1 year and >4 years (mean 5.9 years, SD 2 
years) were chosen as the time points that would be used to represent the clinical course. 
Blood samples were collected at baseline and immediately before the 2- and 6-week 
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infusions and every 8 weeks thereafter. Serum samples from all patients at each of the 
three studied time points (6 months, 1 year and >4 years) could not be obtained. 
Serum IFX assay 
 
The serum Ifx levels were determined by a sandwich ELISA, as has been 
described previously. The cut-off values were established from the serum samples of 
150 healthy blood donors and 100 patients with RA who had never received Ifx (70% of 
whom was RF positive). Serum Ifx levels >10 nag/ml (the mean + 6 SD of the control 
group) were considered positive. 
 
Antibodies to infliximab (ATI) assay 
 
ATI were detected using a two-site (bridging) ELISA as has been previously 
described. The cut-off point for the presence of ATI in patient serum samples was 
established at 50 AU/ml (the mean + 6 SD of the same control group used for the Ifx 
measurements). 
 
Statistical analysis 
 
The descriptive statistics consisted of the mean, SD, median (Mdn) and IQR. 
The statistical analyses were performed using the Statistical Package for the Social 
Sciences, version 10.0 (SPSS, Chicago, Illinois, USA). The frequency data were 
compared using the Pearson χ2 and Fisher exact tests. The continuous data were 
compared between groups using the Mann–Whitney U and Wilcoxon non-parametric 
tests. The time-course data were analyzed using the Kaplan–Meier method. Statistical 
significance was calculated using the log-rank test and p values <0.05 were considered 
significant. 
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ARTICLE 3 
 
TITLE: “The timing of serum infliximab loss or the appearance of antibodies 
to infliximab (ATI) is related with the clinical activity in ATI-positive patients with 
rheumatoid arthritis treated with infliximab” 
JOURNAL: Ann Rheum Dis 2013;72(11):1888–90(103) 
AUTHORS: Ch Plasencia, D Pascual-Salcedo, P Alcocer, M G Bonilla, A 
Villalba, D Peiteado, F Arribas, J Díez, M T Lopez-Casla, E Martín-Mola, A Balsa 
PATIENTS AND METHODS: 
Eleven ATI-positive patients with RA receiving Ifx every 8 weeks were 
included. Disease activity was assessed by DAS28 and European League Against 
Rheumatism (EULAR) criteria at baseline, and during weeks n and n+8. The serum 
drug and ATI levels were determined using a capture and bridging ELISA, as 
previously described, at weeks n, n+4 and n+8. Patients were divided according to the 
findings from week n+4: Group 1 (ATI-positive=without Ifx and ATI-positive, ATI-
negative=with or without Ifx and ATI-negative); Group 2 (with Ifx=ATI-negative and 
with Ifx, without Ifx=ATI-positive or ATI-negative and without Ifx).  
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ARTICLE 4 
 
TITLE: “Predictive Value of Serum Infliximab Levels at Induction Phase in 
Rheumatoid Arthritis Patients” 
JOURNAL: Submitted in: The Open of Rheumatology Journal 
AUTHORS: Jurado Teresa PhD, Plasencia-Rodríguez Chamaida MD, 
Martínez-Feito Ana PhDs, MSc, Navarro-Compán Victoria MD,-PhD, Rispens Theo 
PhD, de Vries Annick PhD, Bloem Karien PhD, Olariaga Eva-María BSc, Diego 
Cristina LT, Villalba Alejandro MD, Peiteado Diana MD, Nuño Laura MD, Bonilla 
Maria-Gema MD, Balsa Alejandro MD,-PhD, Pascual-Salcedo Dora PhD
 
 
PATIENTS AND METHODS: 
Patients and serum samples 
This observational retrospective study included 66 patients with RA recruited 
from a prospective observational RA-Paz cohort. Patients fulfilled the 1987 revised 
criteria of the American College of Rheumatology, had moderate or high disease 
activity (despite previous treatment with disease-modifying anti-rheumatic drugs), and 
were naïve to treatment with biologics; they were followed-up for at least one year, 
except when lost to follow-up for medical reasons and sera from most of the visits (at 0-
2-6-14-22-54 weeks) had to be available. Patients were given intravenous infusions of 
3 mg/kg of Ifx at week (W) 0, 2 and 6 and every 8 weeks thereafter. Serum samples 
were collected at baseline and immediately before each infusion. Disease activity was 
assessed at baseline, W22 and W54 using the Disease Activity Score for 28 joints 
(DAS28) measured according to the erythrocyte sedimentation rate. Therapeutic 
response was evaluated using the EULAR criteria. Patients whose treatment dose was 
modified during the time of the study were excluded. The study was approved by La 
Paz University Hospital Ethics Committee and all patients signed an informed consent 
form. 
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Serum Ifx assay 
Serum Ifx levels were measured by a capture ELISA as previously described. 
Coating antibody (MoAb7 anti-TNF) and buffer (High Performance ELISA buffer) 
were supplied by Sanquin (Amsterdam, The Netherlands). Recombinant TNF was 
supplied by Preprotech and biotinylated anti-idiotype monoclonal antibody for detection 
was supplied by Progenika Biopharma (Derio, Spain). Peroxidase-Streptavidin and 
TMB were used for reaction developing, and optical density was read at 450 nm. The 
cut-off for positivity was 10ng/ml, established with a control group of 250 sera (150 
from healthy donors and 100 from untreated RA patients). Ifx serum levels were 
evaluated at baseline (W0) and at W2, W6, W14, W22 and W54 after initiation of Ifx 
treatment. Serum samples from the 6 time points were available from 43 patients, 
missing a maximum of 2 samples /patient in the rest.  
To determine whether the quantitative or qualitative data obtained by our capture 
ELISA could be extrapolated, we compared our results from University Hospital La Paz 
(UHLP) with two different commercial ELISAs; Promonitor- Ifx (Progenika 
Biopharma, Derio, Spain) and Ifx ELISA-Compact produced by Sanquin (Amsterdam, 
The Netherlands). The Pearson´s correlation coefficients were 0.97 and 0.88, 
respectively (p<0.001 in each comparison), and no discrepancies in positive or negative 
results were found among all three assays (Kappa correlation index ULPH vs Sanquin 
=1; Kappa UHLP vs Promonitor=1) (Supplemental Fig 1). The agreement between drug 
levels of the three different assays was analyzed using an intra-class correlation 
coefficient (ICC); UHLP vs Sanquin (0.907; 95%IC 0.87-0.93; p<0.001) and UHLP vs 
Promonitor (0.64; 95%IC 0.39-0.78; p<0.001). The Bland-Altman plot (Supplemental 
Fig 2) gave an average of differences with a 95% limit of agreement, indicating that the 
two assay methods produce similar results. 
 
ATI detection  
ATI levels were assessed in sera from W0, W2, W6, W14 and W22 of treatment 
in 2 different ways: 
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An in-house 2-site (bridging) ELISA was used to detect uncomplexed (free) ATI 
as previously described. The cut-off value for the presence of ATI was 50 arbitrary units 
(AU)/mL, established from the same serum control group as for IFX levels.  
A commercial kit called IDKmonitor (Immundiagnostik, Bensheim, Germany) 
(A), and an acid-dissociation radioimmunoassay (ARIA, Sanquin) (B), were used to 
measure total (free and complexed) ATI. The (A) assay performed acid dissociation of 
the serum to acquire free ATI. Peroxidase conjugate-Ifx and biotinylated-Ifx were added 
to replace the unmarked therapeutic antibody and the marked Ifx formed a complex 
with ATI that bound via biotin to a streptavidin-coated microtiter plate. Qualitative 
results higher than 10 AU/mL were considered positive. In the (B) assay, an acid 
dissociation was also performed to acquire free ATI. Samples were neutralized in a pH 
7.6 buffer with an excess of Ifx F (ab´) 2-biotin (to replace the unmarked therapeutic 
antibody). Antibodies were subsequently captured by Protein A Sepharose and 
radiolabelled streptavidin was used to detect specific ATI, analogue to the adalimumab 
ARIA. 
Because of the retrospective nature of the study not all serum samples were 
available to be tested in all assays for ATI. Available samples were as follows: W0 (60 
by bridging ELISA, 37 by ARIA and 59 by IDKmonitor); W2 (60 by bridging ELISA, 
58 by ARIA and 60 by IDKmonitor); W6 (64 by bridging ELISA, 63 by ARIA and 63 
by IDKmonitor); W14 (61 by bridging ELISA, 51 by ARIA and 58 by IDKmonitor); 
W22 (60 by bridging ELISA, 51 by ARIA and 57 by IDKmonitor). 
 
Statistical analysis 
Descriptive statistics were reported as mean and standard deviation (SD) or 
median and interquartile range (IQR) depending on normality. Patients were classified 
into two groups depending on the presence or absence of circulating serum Ifx at W54. 
Differences in clinical and biological characteristics between both groups were assessed 
using Pearson’s chi-square test or Fisher’s exact test for categorical variables and the 
Mann-Whitney U test or the Student t-test for continuous variables. Last observation 
carried forward (LOCF) was employed to impute data for patients who discontinued 
treatment before the end of the first year. 
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Serum-dependent ROC curves at W2, W6, W14 and W22 were used to 
determine the ITL that best predicted the absence of free Ifx at W54. The predictive cut-
off was determined as the value for Ifx levels that showed maximum sensitivity, 
maximum specificity and higher positive likelihood ratio at each studied time point. Ifx 
treatment survival was studied using Kaplan-Meier curves and groups were compared 
using the log-rank test.  
Univariable and multivariable logistic regression models were employed to 
investigate the association between early-stage ITL and Ifx at W54. Demographic, 
clinical and serological characteristics (including ITL at W2 and W6 as categorical 
variables) were included in the models as independent variables and the Ifx levels as the 
dependent variable. For all the analysis, Graph Pad Prism 6 (San Diego, CA, USA) and 
SPSS 21.0 software were employed and p-values <0.05 were considered statistically 
significant. 
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ARTICLE 5 
 
TITLE: “Serum tocilizumab trough concentration can be used to monitor 
systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective 
observational cohort study” 
 
JOURNAL: Scand J Rheumatol 2016;0(0):1–8(85)(85) 
 
AUTHORS: EL Kneepkens, IAM van den Oever, CH Plasencia, D Pascual-
Salcedo, A de Vries, M Hart, MT Nurmohamed, A Balsa, T Rispens & G Wolbink 
 
PATIENTS AND METHODS: 
Patient population and study design 
 
This prospective observational cohort consisted of 66 consecutively included 
adult RA patients diagnosed according to the American College of Rheumatology 
(ACR) 1987 revised criteria. All patients started Tcz between April 2009 and 
June 2014. Two cohorts were combined (The Netherlands, n = 34; Spain, n = 32). All 
patients had active disease (DAS28-ESR > 3.2), despite prior treatment with disease-
modifying anti-rheumatic drugs (DMARDs) and/or biologics. All patients started with 
the Tcz standard regimen (8 mg/kg every 4 weeks iv) and concomitant DMARDs with 
or without prednisone, only with concomitant prednisone or TCZ as monotherapy. 
Adaptations in the Tcz regimen could be made, based on the expert opinion of the 
rheumatologist. Patients were eligible for inclusion in the final analyses if a serum 
sample (trough concentration) from at least one follow-up visit from week 12 onwards 
was available, taken after the Tcz standard regimen and in combination with the 
availability of corresponding measurements of DAS28 and/or CRP. The study was 
approved by the Medical Ethics Committee of Slotervaart Hospital and the Jan van 
Breemen Research Institute/Reade, Amsterdam, The Netherlands, and by the Medical 
Ethics Committee of La Paz Hospital, Madrid, Spain.  
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Outcome measures 
 
 In the Dutch cohort, DAS28, parameters of inflammation (CRP and ESR), and 
serum trough samples were collected at baseline and 4, 12, and 24 weeks thereafter. In 
the Spanish cohort, serum samples and parameters of inflammation were collected 
before every Tcz infusion whereas DAS28 and its separate components were measured 
at baseline and at 24 weeks. The duration of follow-up in this study was 24 weeks. 
To investigate the relationship between serum Tcz trough concentration 
(described in the following as Tcz concentration) and clinical response at week 24, 
defined as an improvement compared to baseline in DAS28 (ΔDAS28) and swollen 
joint count in 28 joints (ΔSJC28). To obtain the concentration–effect curve at week 24, 
the last observation carried forward (LOCF) method was used for patients in whom 
follow-up data from week 12 were available but not yet those from week 24. The 
relationship between Tcz concentration and serum CRP (described in the following as 
CRP) was investigated separately as CRP can be used as a surrogate marker for 
systemic IL-6R blockade. 
 
TCZ concentration measurement 
 
To measure Tcz concentrations an immunoassay was developed using rabbit 
ADA to capture Tcz, and rabbit anti- Tcz F (abʹ) 2 fragments for detection. Maxisorp 
enzyme-linked immunosorbent assay (ELISA) plates were coated overnight at room 
temperature with 0.125 μg/mL rabbit anti-Tcz in phosphate-buffered saline (PBS). The 
specific rabbit anti-idiotype antibodies were produced analogously as described for 
natalizumab. Plates were washed five times with PBS/0.02% Tween (PT), then washed 
and incubated for 1 h with patient serum that had been serially diluted in high-
performance ELISA (HPE) buffer. After washing five times with PT, plates were 
incubated for 1 h with biotinylated anti-Tcz F (abʹ) 2 fragments (125 nag/mL in HPE 
buffer). After washing, streptavidin–poly-horseradish peroxidase (poly-HRP); Sanquin, 
Amsterdam, The Netherlands) (1:10 000, in HPE buffer) was added for 1 h at 37°C. 
After washing, the ELISA was developed with 100 μg/mL tetramethylbenzidine in 
0.11Msodium acetate (pH 5.5) containing 0.003% (v/v) H2O2. The reaction was 
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stopped with 2 M H2SO4. Absorption was measured at 450 nm relative to a titration 
curve of Tcz in each plate. The lower limit of quantification (LLOQ) in serum was 200 
nag/mL; the overall precision and accuracy were 8% and 93%, respectively. Serum 
samples were collected at the trough concentrations, that is just before the next infusion. 
 
Anti-Tcz antibody measurement 
 
Measurement of anti-Tcz antibodies was essentially carried out as described 
previously. One microlitre of serum diluted in buffer containing intravenous 
immunoglobulin (IVIg) F(abʹ)2 to prevent ant hinge reactivity was incubated overnight 
with 1 mg Protein A Sepharose (GE Healthcare, Chalfont St Giles, UK) and 2.5 nag 
biotinylated F(abʹ)2 Tcz in a final volume of 800 μL. Subsequently, samples were 
washed with 0.005% PT and about 1 nag 125I-labelled streptavidin was added in a 800-
μL final volume of PBS albumin Tween [PBS/0.01 M ethylene demine- tetra acetic acid 
(EDTA)/0.3% bovine serum albumin/0.004% Tween- 20/0.05% NaN3] and incubated 
overnight. Unbound label was removed by washing and Sepharose-bound radioactivity 
was measured. Antibody levels were compared to a standard serum sample of an 
immunized rabbit containing ADA and expressed in arbitrary units (AU). A lower limit 
of detection was based on mean +3 standard deviations (SD) measured in a panel of 50 
sera from healthy donors and 15 sera containing ACPA, antinuclear antibodies (ANA), 
and/or RF. 
 
Statistical analyses 
 
For statistical analyses, SPSS version 21.0 and Graph Pad Prism 6.0 for 
Windows were used. The results are displayed as number and percentage or mean ± SD 
when normally distributed, or as median and interquartile range (IQR) when non-
normally distributed. For differences in baseline characteristics between patients of the 
Spanish cohort vs. the Dutch, an independent-sample t-test, the Mann–Whitney U test, 
or the χ2 test was used, as appropriate. The threshold for significance was set at p < 
0.05. Spearman’s rank test was used to investigate the correlation between Tcz 
concentration and CRP. A linear regression analysis was used to investigate the 
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relationship between Tcz concentration and ΔDAS28 at week 24. Potential confounders 
of this relationship were investigated using the baseline characteristics, excluding the 
separate components of the DAS28, as the baseline DAS28 was already included. A 
variable was considered to be a confounder if it changed the regression coefficient by ≥ 
10%. For this analysis, the LOCF method was used as described earlier. Sensitivity 
analyses showed no significant difference in baseline characteristics or outcome data 
(ΔDAS28 and Tcz concentrations) at week 12 between patients with and without 
outcome data at week 24. 
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ARTICLE 6 
 
TITLE: “Golimumab trough levels, antidrug antibodies and clinical response 
in patients with rheumatoid arthritis treated in daily clinical Practice” 
 
JOURNAL: Ann Rheum Dis 2014;73(12):2217–9(102) 
 
AUTHORS: Kneepkens, Eva L.; Plasencia, Chamaida; Krieckaert, Charlotte 
L. M.; Pascual-Salcedo, Dora; van der Kleij, Desiree; Nurmohamed, Michael T.; Teresa 
Lopez-Casla, M.; Wieringa, Roeland; Rispens, Theo; Wolbink, Gertjan. 
 
PATIENTS AND METHODS: 
This prospective observational cohort consisted of 37 consecutive adult patients 
with RA, according to the American College of Rheumatology 1987 revised criteria, in 
whom Goli 50 mg subcutaneously once monthly was initiated, and who were recruited 
from two departments (Spain and The Netherlands). The study was approved by both 
Medical Ethics Committees. Clinical response was defined as DAS28-ESR <3.2. 
Patients were eligible for inclusion when clinical data and sera of baseline with ≥ one 
follow-up visit were available. Clinical measurements and trough-level sera were 
collected at baseline and 4, 16, 28 and 52 weeks (The Netherlands), or half yearly 
(Spain), thereafter. Goli levels were measured analogously to adalimumab using TNF 
for capture and rabbit anti-Goli for detection (lower limit of quantification (LLOQ) 5 
nag/ mL; accuracy 103%, precision 12%). ADA were measured, using an ADA radio-
immune assay, described previously. Cut-off (mean+3 SD) was based on a serum panel 
of 80 healthy donors and 15 sera containing ACPA, ANA, and/or RF. For statistical 
analysis SPSS V.17.0 and Graph Pad Prism 5 for windows were used. Threshold for 
significance was set at p<0.05. To analyze the association between Goli levels and 
response at 1 year, last observation carried forward was used for patients who 
discontinued Goli treatment prematurely.  
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Chapter 2: Therapeutic strategies based on monitoring of 
drug and ADA levels 
 
ARTICLE 7: “The immunogenicity to the first anti-TNF therapy determines the 
outcome of switching to a second anti-TNF therapy in Spondyloarthritis patients” 
 
ARTICLE 8: “Effect of infliximab dose increase in rheumatoid arthritis at 
different trough concentrations: a cohort study in clinical practice conditions” 
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ARTICLE 7 
 
TITLE:”The immunogenicity to the first anti-TNF therapy determines the 
outcome of switching to a second anti-TNF therapy in spondyloarthritis patients” 
JOURNAL: Arthritis Res Ther 2013;15(4):R79(118) 
 
AUTHORS: Plasencia, Chamaida; Pascual-Salcedo, Dora; Garcia-Carazo, 
Sara; Lojo, Leticia; Nuno, Laura; Villalba, Alejandro; Peiteado, Diana; Arribas, 
Florencia; Diez, Jesus; Teresa Lopez-Casla, Maria; Martin-Mola, Emilio; Balsa, 
Alejandro. 
PATIENTS AND METHODS: 
Patients and sera 
 
A total of 42 SpA patients from SpA-Paz cohort without previous biological 
treatment were included. This was an ambispective observational study that was 
approved by the La Paz Hospital Ethics Committee, and all patients provided informed 
written consent. All of the AS patients fulfilled the New York revised criteria for AS 
[23]. The psoriatic arthritis patients fulfilled the GRAPPA group criteria. 
All patients received anti-TNF drugs as a first biological treatment Ifx, Ada and 
Etn and later switched to a second anti- TNF drug (Ifx, Ada, Etn and Goli). All 
biologics were administered at standard therapy regimen.  
Disease activity was measured by ASDAS and was assessed at baseline and 
every 6 months. Clinically important improvement was defined as change in ASDAS 
≥1.1. Data related to the clinical activity in the retrospective period were obtained from 
our database of patients on biological therapy. 
Blood samples were collected a maximum of 24 hours before biological drug 
administration for subcutaneous anti-TNF or just before intravenous infusion for Ifx. 
 
 
P 
U 
B 
L 
I 
C 
A 
T 
I 
O 
N 
S 
 Immunogenicity of biological drugs in inflammatory rheumatic diseases: clinical relevance and therapeutic drug monitoring 
 
 
150 
 
Measurement of drug and anti-drug antibody concentrations 
 
The serum drug concentrations (Ifx, Ada and Etn) were determined by sandwich 
ELISA, as described previously. Serum drug levels were considered positive for Ifx if 
>10 nag/ml, for Ada if >5 nag/ml and for Etn if >30 nag/ml. Serum ADA levels 
(antibodies to Ifx, antibodies to Ada and antibodies to Etn) were detected using a two-
site (bridging) ELISA, as previously described. The cutoff value for the presence of 
antibodies to Ifx was established at 50 AU/ml, for antibodies to Ada at 10 AU/ml and 
for antibodies to Etn at 50 AU/ml. 
 
Statistical analysis 
 
The statistical analyses were performed using the Statistical Package for the 
Social Sciences, version 11.0 (SPSS, Chicago, IL, USA). Descriptive statistics included 
the mean and standard deviation or the median and interquartile range. Differences in 
baseline characteristics were assessed using Pearson’s chi-square test and Fisher’s exact 
test for ordinal variables and using the Mann- Whitney U test for continuous variables. 
The continuous data were compared between groups using the Mann-Whitney U test. 
Statistical significance was calculated using the log-rank test, and p < 0.05 was 
considered significant. 
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ARTICLE 8 
 
TITLE: “Effect of Infliximab Dose Increase in Rheumatoid Arthritis at 
Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions” 
 
JOURNAL: Frontiers in medicine 2015; 2: 71(141) 
AUTHORS: Plasencia, Chamaida; Jurado, Teresa; Villalba, Alejandro; 
Peiteado, Diana; Casla, Maria Teresa Lopez; Nuño, Laura; Bonilla, Maria Gema; 
Martinez-Feito, Ana; Martin-Mola, Emilio; Pascual-Salcedo, Dora; Balsa, Alejandro. 
 
PATIENTS AND METHODS 
Patients 
A retrospective observational study was conducted of RA patients from RA-Paz 
cohort, who started treatment with Ifx as the first TNFi. The following inclusion criteria 
were used: RA patients (older than 18years) treated from 2005 to 2011 who exhibited 
an insufficient clinical response defined as DAS28 >3.2, who received an increase in Ifx 
dose therapy regimen, and who had serum sample and clinical assessment data during 
the first year of therapy. A final observation was carried forward for analysis in patients 
who stopped Ifx treatment within the first year after dose increase. This study was 
approved by the research ethics committee of the Hospital Universitario La Paz. 
 
Treatment  
Initially all patients received standard therapy regimen of Ifx. The dose of Ifx 
was intensified by rheumatologist criteria and clinical response of patients. Dose 
escalation could also be combined with increasing doses of DMARDs and/or 
corticosteroids.  
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Data Collection and Assessments  
Medical history, demographic data, ACPA, and RF were retrospectively 
retrieved prior to Ifx increase (baseline). DAS28score, EULAR response, and serum 
concentrations of Ifx and ATI were also retrieved at baseline (T1), after the first Ifx 
dose increment (T2), and at 6 months (T3), and 12 months (T4). ACPA were measured 
using ELISA, and RF was assessed using nephelometry. 
 
Infliximab Serum and ATI Concentrations  
Serum Ifx concentrations were determined using a capture ELISA Serum ATI 
levels were assayed using a two-site (bridging) in-house.  
 
Statistical Analysis  
Descriptive statistics are provided as the mean, SD, median and interquartile 
range (IQR).A fixed effects analysis of repeated measures was performed, and 
Bonferroni correction was used for multiple comparisons. Qualitative variables were 
compared at different time points between different groups using Fisher’s test, and the 
Bonferroni test was used for multiple comparisons. A regression mixed model for 
repeated measurements was performed using group (no, low, and high Ifx levels) and 
time points (T1, T2, T3, andT4) as factors to compare DAS28 and delta-DAS28 
between groups. Interactions between factors were calculated as fixed effects, and 
subjects were calculated as random effects. Pair-wise comparisons were calculated 
using Bonferroni correction. EULAR was analyzed using a generalized linear model 
with cumulative logit link function. A significance level of 0.05 was used for statistical 
testing, and all analyses were performed using SAS9.3 (SAS Institute, Cary, NC, USA). 
Patients were assigned to one of three serum Ifx groups: no detectable, low (<1.1 
μg/mL) or high (≥1.1 μg/mL). These cut- off levels were based on the observation that 
serum Ifx >1 mg/L (12) was associated with improved disease. 
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Chapter 3: Tapering or Discontinuation strategies in 
rheumatic patients 
 
ARTICLE 9: “Anti-TNF discontinuation and tapering strategies in patients with 
axial spondyloarthritis: a systemic literature review” 
 
ARTICLE 10: “Comparing tapering strategy to the standard dosing regimen of 
TNF inhibitors in rheumatoid patients with low disease activity” 
 
ARTICLE 11: “Comparing tapering strategy to the standard dosing regimen of 
TNF inhibitors in spondyloarthritis with low disease activity” 
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ARTICLE 9 
 
TITLE: “Anti-TNF discontinuation and tapering strategies in patients with 
axial spondyloarthritis: a systematic literature review” 
JOURNAL: Rheumatology 2016;55:1188-1194(142) 
AUTHORS: Victoria Navarro Compán; Chamaida Plasencia Rodríguez; 
Eugenio de Miguel; Alejandro Balsa; Emilio Martín Mola; Daniel Seoane Mato; Juan D 
Cañete. 
PATIENTS AND METHODS: 
 
Research question and search strategy 
 
A systematic literature review (SLR) was performed using Medline, EMBASE 
and Cochrane databases in collaboration with an epidemiologist with expertise on SLR 
methodology. The search included studies published in English, Spanish or French up to 
4 September 2014. The research question was formulated according to the Population, 
Intervention, Comparison, Outcome and Study design (PICOS) method, in which each 
of the items was defined as specified below. LDA and clinical remission were not pre-
defined, but the exact definition used in each study was collected. 
The population was patients with axial SpA (axSpA), AS or non radiographic 
axSpA (nraxSpA), who achieved LDA or clinical remission after receiving a standard 
dose of anti-TNF therapy. Two intervention strategies were evaluated: discontinuation 
of anti-TNF therapy or tapering (dose reduction compared with the standard dose) anti-
TNF therapy. Comparison was made with maintaining a standard dose of anti-TNF. The 
outcome was flare or change (increase) on disease activity parameters. As there is no 
accepted definition for flare in axSpA, this was not pre-defined, but the exact definition 
employed in each study was also collected. Longitudinal studies with at least 6 months 
of follow-up since the intervention (strategy) started were included. 
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Selection of studies 
 
First, titles and abstracts of the retrieved citations were screened to select articles 
for full-text review. Later, based on the full-text reading of the selected articles, two 
readers independently decided whether or not to include a specific study for data 
extraction and, in instances of disagreement, they discussed until a consensus was 
reached. Inclusion criteria were based on the PICOS components. Exclusion criteria 
were non-compliance with the definitions established on the PICOS or insufficient data 
provided by the article to evaluate the objective of the present study. 
 
Data extraction and data summary 
 
Using a systematic extraction data form developed for this specific purpose, both 
reviewers independently extracted data for each study, including the following: 
characteristics of the studies (year of publication, design and follow-up period) and 
patients (total number of patients, demographics and disease characteristics); definition 
of LDA or clinical remission used in the study; intervention (anti-TNF therapy and dose 
regimen); and outcome (definition and percentage of patients who achieved the specific 
outcome). Furthermore, we also evaluated the quality and potential biases of the studies, 
assigning an overall quality score per study between 0 and 5 points according to the 
Oxford level of evidence. To summarize the extracted data, the studies selected for data 
extraction were classified in two groups based on the type of intervention strategy, 
namely discontinuation or tapering. 
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ARTICLE 10 
 
TITLE: “Comparing a tapering strategy to the standard dosing regimen of 
TNF inhibitors in rheumatoid arthritis patients with low disease activity” 
 
JOURNAL: Clinical and Experimental Rheumatology 2016;34:000-000(143) 
AUTHORS: C. Plasencia, G. Wolbink, C.L.M. Krieckaert, E.L. Kneepkens, S. 
Turk, T. Jurado, A. Martínez-Feito, V. Navarro-Compán, G. Bonilla, A. Villalba, D. 
Peiteado, L. Nuño, E. Martín-Mola, M.T. Nurmohamed, D. van der Kleij, T. Rispens, 
D. Pascual-Salcedo, A. Balsa 
 
PATIENTS AN METHODS: 
Patients, clinical assessment and therapy regimen 
 
In this retrospective observational study two RA cohorts on TNFi were 
analyzed: a cohort from Spain under a tapering strategy (tapering group: TG) and a 
cohort from the Netherlands on standard therapy regimen (control group: CG). A total 
of 493 RA patients (233 from Spain and 260 from the Netherlands) were under TNFi 
(Ifx, Ada and Etn) but only 144 patients fulfilled the inclusion criteria for this study (67 
patients from Spain and 77 patients from the Netherlands). All the selected RA patients 
fulfilled the1987 ACR revised criteria for RA, signed an inform consent before starting 
TNFi. 
Consecutive RA patients treated with TNFi from Spain, who were under a 
tapering strategy with low disease activity or remission (DAS28<3.2) for at least 6 
months before starting the tapering, were selected. Next, consecutive RA patients 
treated with TNFi from the Netherlands and in low disease activity or remission for at 
least 6 months were chosen. Later, both cohorts were matched according to several 
demographic, serological and clinical characteristics to ensure that both groups were 
similar at baseline and at visit 1(before starting the tapering strategy. RA patients who 
did not fulfill these requirements were excluded from the study to avoid 
misinterpretations using heterogeneous cohorts.  
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The tapering strategy included a progressive interval prolongation: the interval 
administration in Ifx and Ada was prolonged 1 week every time and in Etn was delayed 
3 days every time as long as the physician decided that the interval of administration 
could be modified based on clinical and serological markers. The CG remained on the 
standard dose of biologic therapy throughout the study. Initially, Ifx was administered 
intravenously at 3 mg/kg at 0, 2 and 6 weeks and every 8 weeks thereafter, and the 
remaining TNFi were administered subcutaneously (Ada: 40 mg/2 weeks and Etn: 50 
mg/week). Clinical activity was measured using DAS28 at different time points: visit 0 
(just prior to starting the TNFi), visit1 (before beginning the taper in the TG and at least 
6 months with low disease activity in the TG and CG), visit 2 (6 months after visit 1), 
visit 3 (1 year after visit 1), visit 4 (the last visit available after visit 1) and visit flare 
(the visit with the worst flare between visit 1 and visit 4). Flares were registered 
between visit 1 and visit 4; a flare was defined as a DAS28 ≥3.2 and delta-DAS<0.6 
comparing to DAS at visit 1 on at least one occasion. If a flare occurred in the TG, the 
interval of biological drugs could be shortened to regain low disease activity and also 
prednisone, non-biologic DMARDs and/or NSAID could be intensified. When a flare 
was registered in the CG, intensification in prednisone, non-biologic DMARDs and/or 
NSAID treatment was used to regain control over the disease activity. 
 
Serum samples and assays to measure drug and ADA levels 
 
The serum drug concentrations (Ifx, Ada and Etn) were determined by in house 
capture enzyme-linked immunosorbent assay (ELISA). The radioimmunoassay (RIA) 
by Sanquin Diagnostic Services (Amsterdam, the Netherlands) was performed to detect 
ADA in patients treated with Ifx and Ada. Both measurements, the drug and ADA 
levels, were measured in most patients of the TG in the different time studied points. In 
the CG from the Netherlands, only ADA levels were measured. In general, drug and 
ADA levels were measured in 65 out of 67 (97%) patients in the TG and ADA levels 
were tested in 71 out of 77 (92%) patients in the CG. 
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Statistical analysis 
 
First, descriptive analyses were performed for the demographic and clinical 
variables. The results are shown as means and standard deviation (SD) for continuous 
variables and relative frequencies for categorical variables. The frequency data were 
compared using the Pearson χ2 and Fisher exact tests. The continuous data were 
compared between groups using the Mann- Whitney U non-parametric test. Later, the 
associations between the independent variables and the outcomes were investigated 
using univariate logistic regression model. Estimates for these associations are shown as 
standardized linear coefficient. SPSS 20.0 software was employed for the analyses and 
p values less than 0.05 were considered statistically significant. 
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ARTICLE 11 
 
TITLE: “Comparing Tapering Strategy to Standard Dosing Regimen of 
Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease 
Activity.” 
 
JOURNAL: The Journal of Rheumatology 2015;42: 1638-1646(144) 
AUTHORS: Plasencia, Chamaida; Kneepkens, Eva L.; Wolbink, Gertjan; 
Krieckaert, Charlotte L. M.; Turk, Samina; Navarro-Compan, Victoria; L'Ami, Merel; 
Nurmohamed, Mike T.; van der Horst-Bruinsma, Irene; Jurado, Teresa; Diego, Cristina; 
Bonilla, Gema; Villalba, Alejandro; Peiteado, Diana; Nuno, Laura; van der Kleij, 
Desiree; Rispens, Theo; Martin-Mola, Emilio; Balsa, Alejandro; Pascual-Salcedo, Dora 
 
PATIENTS AND METHODS: 
Patients, clinical assessment and therapy regimen  
 
In this retrospective observational study, 2 SpA cohorts taking TNFi were 
analyzed: a cohort from Spain under a tapering strategy (tapering group: TG) and a 
cohort from the Netherlands taking a standard therapy regimen (control group: CG). 
First, 528 patients with SpA (282 from Spain and 246 from the Netherlands) under 
TNFi (Ifx, Ada and Etn) were recruited, but after the selection period only 117 patients 
with SpA fulfilled the inclusion criteria (74 patients from Spain and 43 patients from the 
Netherlands). The number of patients from the Netherlands was lower because no 
control group was available for Ifx and during the matching process of both cohorts; 
several patients with SpA were excluded.  All the selected patients with SpA had axial 
involvement and 49% (58) of them had also had some peripheral manifestations 
(arthritis, enthesitis, and dactylitis). The patients with AS fulfilled the revised New York 
criteria, and the remaining patients with SpA with non-radiographic axial SpA fulfilled 
the Assessment of Spondyloarthritis Society classification and diagnostic criteria. All 
the included patients with SpA had a sustained LDA of at least 6 months, defined by 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4, and also fulfilled 1 
of these conditions: normal C-reactive protein (CRP) or ΔBASDAI > 50%. 
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Disease activity was measured by BASDAI at the different time points: visit 0 
(prior to starting TNFi), visit 1 (before starting the tapering strategy in TG and after at 
least 6 months with LDA in the TG and CG), visit 2 (6 months after visit 1), visit 3 (1 
year after visit 1), visit 4 (the last visit available after visit 1), and visit flare [visit with 
(the worst) flare between visit 1 and visit 4]. Clinical activity was monitored every 6 
months during the study, and the same periods of clinical evaluations were considered 
in the control group to avoid overestimating flares.  
The tapering strategy was done as follows: in Ifx-treated patients, the tapering 
strategy included a gradual dose reduction (5 mg/kg to 4 mg/kg to 3 mg/kg) and/or 
interval administration per weeks (8 weeks to 9 weeks to 10 weeks, to a maximum of 15 
weeks), ADA administration was prolonged 1 week until a maximum of 6 weeks and 
ETN was delayed 3 days for a maximum of 3 weeks as long as the physician decided 
that the interval of administration could be modified based on clinical and serological 
markers. The CG continued the standard therapy regimen throughout the study. The 
patients gave written informed consent prior to the start of the biological therapy. 
Flares were recorded during the follow-up after visit 1 and were defined as 
BASDAI ≥ 4 and a ΔBASDAI ≥ 2 in comparison with the BASDAI at pre-tapering 
(visit 1). In the TG, in a flare episode, the TNFi dose could be increased or the interval 
could be shortened to regain low disease activity. When a flare was registered in the 
CG, an intense regimen of non-steroidal anti-inflammatory drugs (NSAID) and/or non-
biologic disease-modifying anti-rheumatic drugs (DMARD) was used to control the 
disease activity. 
In the selection period, the first step was to select a SpA cohort from Spain 
under tapering strategy who fulfilled the inclusion criteria. Later, both cohorts were 
matched according to several demographic, serological, and clinical characteristics to 
ensure that both groups were similar at baseline and at visit 1 (before starting the 
tapering strategy).  
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Serum samples and assays to measure drug and antidrug antibody levels 
 
The serum drug concentrations (Ifx, Ada, and Etn) were determined by ELISA. 
A radioimmunoassay was performed to detect antidrug antibodies in the patients with 
SpA.  
Statistical analysis  
 
First, descriptive analyses were performed for the demographic and clinical 
variables. The results are shown as means and SD for continuous variables and relative 
frequencies for categorical variables. The frequency data were compared using the 
Pearson chi-squared and Fisher exact tests. The continuous data were compared 
between groups using the Mann-Whitney U and Wilcoxon nonparametric tests. Later, 
the associations between the independent variables and the outcomes were investigated 
using a univariate logistic regression model. Estimates for these associations are shown 
as standardized linear coefficient. SPSS 20.0 software was used for the analyses, and p 
values < 0.05 were considered statistically significant. 
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Chapter 4: Economic repercussion of tapering strategies 
monitoring drug/ADA levels (TDM) 
 
ARTICLE 12: “Dose-Tapering of TNF inhibitors in daily rheumatology practice 
enables the maintenance of clinical efficacy while improving cost-effectiveness” 
 
ARTICLE 13: “Anti-TNF dose and anti-drug antibody levels in rheumatic and 
psoriasis patients: economic repercussion” 
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ARTICLE 12 
 
TITLE: “Dose-Tapering Of TNF Inhibitors in Daily Rheumatology Practice 
Enables the Maintenance of Clinical Efficacy While Improving Cost-Effectiveness” 
 
JOURNAL: Pharmacovigilance 2015;3:4 2329-6887(145) 
 
AUTHORS: Dora Pascual-Salcedo, Chamaida Plasencia, Teresa Jurado, Luis 
González del Valle, Prado Sabina, Cristina Diego, Alejandro Villalba, Gema Bonilla, 
Ana Martínez-Feito, Emilio Martín-Mola and Alejandro Balsa 
 
PATIENTS AND METHDOS: 
This is a retrospective observational study which develops in two different time 
periods. In the first period (1st P) from 2007 to 2009 (2.02 ± 0.84 years), the patients 
were treated with a standard therapy; in the second period (2nd P), from 2010 to 2012 
(2.42 ± 0.33 years), they were treated with a tapering strategy. This study design 
allowed the patients to be their own controls because the same individuals were 
compared in both time periods.  
To be included in the study, patients had fulfilled these criteria: i) to be for at 
least six months sustained LDA (defined in RA patients by the DAS28<3.2 and in axial 
SpA patients by the BASDAI<4 with one of these conditions: normal C-reactive protein 
(CRP) or delta-BASDAI>50%); ii) to be treated with the same TNF inhibitor 
throughout the entire study and iii) to have received treatment in both study periods. 
Seventy seven patients (36 (46.7%) with RA and 41 (53.3%) with SpA) out of 
the total of 395 treated with Ifx, Ada or Etn in the Rheumatology Department from La 
Paz University Hospital, met these inclusion criteria. All RA patients fulfilled 
the 2010 or 1987 ACR revised criteria and all SpA patients have axial involvement and 
fulfilled the New York revised criteria or the ASAS group criteria. 
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Clinical activity was evaluated at baseline and every 6 months by the DAS28 in 
RA patients and by the BASDAI in SpA patients. BASDAI was used to evaluate SpA 
patients instead of ASDAS because no ASDAS values were available at the beginning 
of the study period. This was an observational study that did not require the approval of 
the Hospital Ethical Committee. 
The tapering strategy consisted in a progressive interval prolongation (increasing 
the interval of Ifx and Ada administration by one week and of Etn administration by 3 
days) and/or dose reduction (decreasing by 1 mg/kg until 3 mg/kg in SpA patients 
treated with Ifx) following the physician criteria based on clinical and serological 
markers CRP, erythrocyte sedimentation rate-ESR- and TNFi levels). A flare was 
defined as an increase of the DAS28-ESR (a composite score measuring disease 
activity) greater than 3.2 plus a delta-DAS28 (related to pre-tapering DAS28) lower 
than -0.6 in RA patients and BASDAI ≥ 4 and delta-BASDAI ≤-2 (related to pre 
tapering BASDAI) in SpA patients in at least one clinical visit during the study. In the 
case of a flare, the concomitant therapy (disease-modifying anti-rheumatic drugs-
DMARDS-, non-steroidal anti-inflammatory drug -NSAIDS-, corticosteroids) could be 
intensified in both periods, but the TNFi therapy was only increased in the 2
nd
 P. 
Out of the 77 patients, 29 were treated with Ifx, 27 with Ada, and 21 with Etn. In 
the 1st P, Ifx was administered intravenously to RA patients at 3 mg/kg at 0, 2, 6 weeks 
and every 8 weeks thereafter; and to patients with SpA at 5 mg/kg at 0, 2, 6 weeks and 
every 8 weeks thereafter. Ada was administered at 40 mg/2 weeks and Etn at 50 mg/ 
week following the drug labels. In the 2nd P, clinicians were allowed to increase the 
administration interval and/or reduce dose in case of Ifx if the patient was presenting 
LDA. 
Blood samples were collected a maximum of 24h before the biologic drug 
administration for a subcutaneous TNF inhibitor or just before intravenous (iv) infusion 
for Ifx. Drug and ADA levels were measured at every visit for patients on Ifx treatment 
and every 6 months for patients on subcutaneous administration. 
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Measurement of drug and ADA concentration 
 
Serum drug concentrations were determined by a ELISA. Cut-off values for 
positive drug levels were 10nag/ml for Ifx, 5nag/ml for Ada and 30nag/ml for Etn. 
Serum ADA levels were assayed using a two-site (bridging) in-house ELISA. 
 
Evaluation of the dispensed amount of drug and cost analysis 
 
The drug amount that each patient received was obtained from the database of 
the Pharmacology Department. We evaluated the mean dose delivered to the patient and 
the mean time elapsed between the dispensations in both periods of the study. With 
these data, the mean weekly dose was calculated. The cost of the treatment in each 
period was calculated taking the price of each medication at the end of 2012 into 
account. 
 
Statistical analysis 
 
Differences in baseline characteristics were assessed using Pearson’s chi-square 
test and Fisher’s exact test for ordinal variables. Continuous non-parametric data were 
compared between groups using the Mann- Whitney U test. Paired comparisons of 
parametric results were performed by Student’s t-test and non-parametric results by the 
Wilcoxon matched-pairs test. p-values were considered significant when under 0.05. 
Statistics were performed using Graph Pad Prism6 software (San Diego, CA, EEUU). 
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ARTICLE 13 
 
TITLE: “Anti-TNF dose and anti-drug antibody levels in rheumatic and 
psoriasis patients: economic repercussion” 
JOURNAL: Eu J Clin Pharm 2015; 17(2): 95-104(146) 
AUTHORS: González Fernández Maria Ángeles, Moreno Ramos Francisco, 
Varela Hugo Adolfo, Plasencia Chamaida, Pascual Salcedo Dora, Herranz Pinto 
Pedro, Herrero Ambrosio Alicia.  
PATIENTS AND METHODS: 
This is an ambispective observational study (2009-2012: without optimization 
strategy and from 2013: with optimization strategy) including patients with rheumatic 
diseases or psoriasis under biological therapy and in whom an optimization strategy was 
started. All optimized patients sustained a good clinical response.  
Pharmacist reviews the prescriptions of all the patients treated with biological 
therapies when they are dispensed in the Pharmacy Department. Dosage regimens for 
all patients were checked.  
A number, corresponding to the number of months that the amount of 
medication given to the patient would cover, was given to every dispensing process. 
This transformation is necessary in order to obtain the values of certain, parameters such 
as dispensed-patient-month, average-dispensed-patients and annual cost per average-
patient established by the Healthcare System of the Community of Madrid.  
 
Calculation of the dispensed-patient month, average-dispensed-patient and 
annual cost per average-patient 
Annual cost per average-patient= Aggregate cost of biological drug/Mean 
dispensed-patient.  
Aggregate cost was defined as the aggregate expenditure by average book price.  
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Annual average-dispensed patient was defined as the average of the dispensed-
patient-months that have received treatment during the year.  
 
Calculation of the annual costs per average-patient under biological treatment 
and per drug.  
The aggregate-cost per average patient per year was calculated for each of the 
pathologies included in this study.  
The statistical analysis consisted in calculating the statistical significance with 
Student´s test of the difference of proportions.  
Finally, annual results obtained per patient in 2013 were compared to those 
calculated in previous years, and to the cost-per-drug for pathology in 2013. Thus, we 
were able to analyze the economic impact of the optimization of biological treatments.  
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In the present work, we have shown the results from a deep research about a 
very important topic: the immunogenicity of biologics and its clinical relevance in 
rheumatic patients. From the beginning of the biological treatment, it was seen that a 
group of patients had primary or secondary inefficacy. As a result of the monitoring of 
drug and ADA levels, we have been able to see a huge variability of drug concentrations 
in patients with the same pathology under the same biologic regimen.  
Our initial studies demonstrated the correlation between serum trough drug and 
ADA levels with clinical outcomes in RA and SpA patients from the biologic cohort 
from the La Paz University Hospital(73,96,103). Later, we investigated if serum trough 
drug and ADA monitoring could be useful to make therapeutic decisions in patients 
under TNFi treatment who develop a drug failure(118,141).  
Currently, it is more common to have patients with sustained low disease 
activity under long-standing biologic therapy. The tapering strategy of biologics 
(decreasing dose or increasing the interval of administration) seems feasible and has 
been more frequently used in the last years(142). One of the main concerns for 
clinicians is the appearance and management of flares in patients under a tapering 
strategy. We presented  two observational studies comparing the tapering strategy to the 
standard therapy regimen in RA and SpA patients in clinical practice(143,144). These 
works are relevant because they show that a progressive tapering strategy is feasible in 
clinical practice because it entails similar clinical outcome as patients under a standard 
therapy regimen(143,144).  
Finally, another concern for our health system is the cost of biopharmaceuticals 
in patients with rheumatologic diseases for two obvious reasons: its high cost and 
because its use is increasing due to the prevalence of these diseases. Referring to this 
topic, we carried out two studies demonstrating that adequate clinical monitoring 
together with tools such as drug monitoring can help optimization strategies to be 
carried out more safely with a significant reduction of costs(145,146). 
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Association between serum drug and ADA levels with 
clinical outcomes 
 
As previously reported, both in RA and SpA patients treated with Ifx, we have 
found that serum Ifx trough levels are inversely correlated with clinical response. In 
addition, undetectable serum Ifx levels were associated with ATI 
appearance(25,48,104,147). Other authors have also shown that ATI+ patients were 
more often classified as non-responders than ATI-(68,71,93,94). These studies have 
shown this relationship in shorter follow-up periods compared to ours, which included 
follow-up of up to 4 years. A study with a comparable duration time is the one 
performed in a Dutch RA cohort of 272 patients treated with Ada(47). In this 
population, they observed similar correlation between ADA statuses and the clinical 
response(47). Furthermore, another work in SpA patients treated with Ada observed a 
significant inverse correlation between Ada levels and clinical activity measured by 
ASDAS and with ADA titres(76).  
Drug survival is another indirect parameter related to clinical efficacy that has 
been evaluated in several studies. Most publications observed that ADA+ patients have 
more frequent discontinuations and a less biological drug survival(47,71). In our cohort 
under Ifx therapy, the proportion of ATI+ patients who discontinued the drug was high, 
being 82% in RA and 73% in SpA patients. Moreover, the Ifx survival was significantly 
lower in patients with detectable ATI in comparison with patients without ATI(73,96).  
As has been explained in the introduction, not all biological drugs have the same 
immunogenic ability and structural differences can influence both the production of 
antibodies and their ability to be detected with currently available assays(54,56,61,63). 
In patients treated with Etn, Goli or Tcz, the frequency of ADA is low or practically 
nonexistent(54,85,102,148,82,149,81,84,89). However, a clear correlation has been seen 
between serum trough drug levels and clinical outcomes. In a cohort of 292 RA patients 
treated with Etn, serum Etn levels were significantly higher in good responders as 
compared to both moderate and EULAR non-responders after 6 months of therapy(95). 
Kneepkens et al. observed in an AS cohort of 162 patients that Etn levels were 
significantly higher in patients with ASDAS<2.1compared to ASDAS≥2.1 
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patients(148). When patients were categorized into quartiles according to Etn levels, the 
lowest quartile (Etn<1.80 mg/L) comprised 35% of all patients with ASDAS≥2.1 while 
the highest quartile comprised only 14%. No antibodies against Etn were detectable in 
this study(148). Our group also carried out studies with less immunogenic TNFi such as 
Goli in RA patients(102). With Goli, an inverse correlation between clinical activity and 
serum drug levels was noted(102). After stratifying patients into groups according to 
drug levels, inactive patients appeared in the highest quartiles(102). We only found that 
3 out of 37 patients were ADA+ and all of them discontinued therapy due to 
inefficacy(102). The proportion of patients who developed ADA during Goli treatments 
varied between 2.1%-15.2% (58,149,89). Chen et al. found the highest proportion of 
ADA+ RA patients under Goli treatment (15.2%) possibly due to the lower number of 
patients taking concomitant immunosuppressive drugs like MTX, the lower dose of 
MTX, differences on the assays and the small sample size(89).  
Tcz is a humanized antibody that competitively inhibits soluble and membrane-
bound IL6R(150). For the TNFi therapy, it has been shown that immunogenicity can 
have a profound effect on the PK(21,22,24,25,27,49,54,57,151). Nevertheless, the PK 
of Tcz appears to be different. In our study, only 1 patient had detectable antibodies 
against Tcz. On the other hand, lower serum trough Tcz concentrations (below 1 mg/L) 
were found in several patients(85). The influence of immunogenicity might have been 
underestimated in this study because the assay to detect anti-Tcz antibodies is a drug 
sensitive one, meaning that only ADA exceeding Tcz concentration will be 
detected(85). Recent publications evaluating the immunogenicity of Tcz confirm that 
the immunogenicity in RA patients under Tcz treatment is very rare(82,81,84) and 
similarly to our work, an Italian cohort showed that clinical response is better in patients 
with higher serum trough Tcz levels (10 μg/ml) than those with lower levels(84). 
With all the above exposed data, there are no doubts about the relationship 
between clinical outcomes and drug immunogenicity. Nevertheless, no plausible 
explanation for the partial clinical response reported in some ATI+ patients is found. In 
fact, in our previous work in rheumatic patients under Ifx treatment, 24% of RA and 
17.6% of SpA patients were responders with ATI+(72,73). This fact motivated our 
research group to investigate whether the timing of ATI appearance and/or drug 
disappearance between 2 infusions correlated to clinical outcomes. In 11 ATI+ patients 
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with RA, we saw that the effect of Ifx was closely correlated to the timing of the drug 
disappearance (related to ATI detection) between infusions(103). Another relevant 
finding was that higher ATI levels were found in patients with earlier drug clearance 
between 2 infusions. It has to be clarified that these findings were seen in a small cohort 
of patients but contribute to partially understand why not all ATI+ patients have poor 
clinical response(103).  
Another important aspect is whether immunogenicity is an early event that can 
only be detected in the first months of treatment or whether it can occur at any time 
during therapy. In our patients, ATI detection occurred mainly in the first year (Mdn of 
16 weeks in RA and 44 in SpA) but in some patients, ATI detection was delayed for >1 
year and in SpA patients ATI was detected later than in RA patients. This may be due in 
part because dose of Ifx is different in both diseases and in previous studies it has been 
described that ATI detection is inversely correlated to the dose(72,73).  
 
Association between immunogenicity and concomitant 
therapy with MTX 
 
Several publications have demonstrated the effect of the immunosupresive drugs 
such as MTX or AZA on the immunogenicity in patients under biologics(5,45–48,71–
73,93,105–107). The first study emerging on this topic involved RA patients under Ifx 
treatment, and it described that MTX has a synergistic effect(5). Similar findings have 
been noted in rheumatic patients treated with other TNFi such as Ada, 
Goli(47,106,107). In our cohort of RA patients, we saw that the drug survival was 
longer in patients with concomitant therapy and in the subgroup of ATI+ patients with 
RA, the antibody titers were lower in patients taking MTX(72).  
However, the role of MTX in SpA is not clear because it is known that 
DMARDs have no effect on axial involvement(45,48,73,109). In our study of SpA 
patients treated with Ifx, concomitant treatment with MTX not only showed that 
frequency of ATI was lower, but also that in the subgroup of ATI+ patients, ATI titers 
were lower and detection occurred later than patients under monotherapy(73). The 
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effect of MTX in preventing the ADA development is not completely understood 
because it is not clear whether this effect is related to a synergistic or an anti-
immunogenic effect.  
Further publications have demonstrated that the effect of DMARDs such as 
MTX preventing ADA development is dose-dependent(46,50). Krieckaert et al. 
demonstrated that the probability to detect ADA is lower for patients with higher MTX 
dose than in patients under monotherapy or with lower MTX dose(50). Another 
publication including RA and PsA patients assessed the effect of MTX and other 
DMARDs on serum Ada trough concentrations(46). They observed that Ada trough 
concentrations are the highest in patients receiving MTX, (with or without other 
DMARDs) and patients under Ada monotherapy had the lowest serum concentrations. 
Although MTX seems to have the strongest influence on Ada trough concentrations, 
other DMARDs also seem to have a beneficial effect on drug levels(46).  
 
Association between immunogenicity and adverse events 
 
ADA related adverse drug reactions may appear with TNFi. The most frequent 
ADA-related side effects are infusion reactions, mainly with Ifx and Rtx, and injection 
reactions to subcutaneously administered drugs(71,93,104,110,111,113,152–155). Most 
mild reactions and injection side reactions are solved within 24 hours and can be treated 
with anti-histaminic drugs and/or corticosteroids(111). Severe reactions have been 
described with Ifx(111). The close correlation between infusion related reactions and 
ATI levels, in patients under Ifx, has been described in several studies including 
ours(49,71,73,96,155). 
Local injection reactions are frequently seen in patients who receive a 
subcutaneously biological drug. The relation to antidrug antibody formation is, 
however, unclear. In some patients treated subcutaneously with biological drugs a 
systemic response is observed, but little information is available on the clinical effects 
of chronic immune-complex formation in these patients(111). The immunoglobulin 
IgG4 is an IgG isotype that has been described by some authors as potentially causing 
transient sensitization that leads to signs and symptoms comparable with those induced 
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by IgE-mediated reactions; initially termed as IgG short-term sensitizing(156). A 
previous study showed the presence of IgG4 anti-Etn in 13% of patients with injection-
site reactions, which may predict a lower response to Etn therapy in patients(156).  
 
Usefulness of monitoring early drug levels  
 
A very important issue for clinicians is to find predictors of good clinical 
response at baseline or during the induction phase of the biopharmaceuticals. Patients 
with rheumatic diseases have an important disability when the disease is active and it is 
crucial to find the best therapeutic target for each patient as soon as possible to avoid 
inefficient therapies. Some authors have described that monitoring serum drug levels at 
early stages of the biological therapy can be related with future clinical outcomes and 
with ADA detection(71,94,104,119,121,148). Bendtzen et al. were the first to find that 
low Ifx levels at 1.5 months predicted antibody development and subsequent treatment 
failure in a cohort of 106 RA patients under Ifx therapy(104). A French group analysing 
a RA and SpA cohort observed that as early as week 2, Ifx levels were lower in patients 
who were later classified as ATI+(71). For other TNFi such as Ada or Etn, the 
correlation between the initial drug levels and the clinical response has also been 
demonstrated(44,119).  
Other studies try to combine the monitoring of early drug levels with the initial 
clinical evaluation. Kobayashi et al. observed in a cohort of ulcerative colitis (UC) that 
early Ifx levels (at week 2), in combination with clinical evaluation are useful to predict 
short-long-term outcomes(120). In a small cohort of 57 RA patients treated with Ifx it 
was found that the combination of DAS28 at week 6 of therapy with Ifx trough levels 
could be predictors of clinical response at 6 months(121).  
It is not clear why patients under Ifx therapy receiving the same dose at 
induction phase (adjusted by weight) have wide differences in serum trough drug levels. 
Our group demonstrated that early ATI production is detected in some patients with low 
levels at induction phase. Moreover, immune-complexes formed by ATI and Ifx as early 
as week 2 of treatment can be detected using drug tolerant assays(61,63,65). On the 
other hand, we defined a cut-off at early stages to predict ATI development and clinical 
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response during the first year of Ifx therapy using ROC analysis. Our predictive cut-off 
for Ifx is very similar to the one defined by Kobayasi in patients with IBD(120). These 
findings indicate that serum trough drug levels monitoring could be a useful tool to 
define which patients are more prone to have a poor clinical response.  
 
Therapeutic strategies based on monitoring serum drug 
and ADA levels  
 
In clinical practice, it is not uncommon for patients under biologic therapy like 
TNFi to experience a primary or secondary inefficacy and require switching to another 
biologic. In the guidelines, all options are allowed to switch to a second TNFi or change 
the mechanism of action(122,157,158). It is also crucial to consider that not all 
rheumatic pathologies have the same therapeutic options and before making hasty 
decisions, the best treatment for each patient should be considered. This fact motivated 
some authors to investigate if the immunogenicity against a first TNFi may affect the 
clinical response to a second TNFi. In a dutch RA cohort who received a first TNFi as 
Ifx or Ada and switched to Etn, it was observed that the clinical improvement in 
switchers with antibodies against the first TNFi was similar than TNF naïve 
patients(123). But switchers without antibodies to the first TNFi had a lower delta-
DAS28 than TNFi naive and switchers with previous antibodies(123). Similar findings 
were confirmed by our group in SpA patients who switched to a second TNFi(118). 
These data suggest that for patients who fail due to inefficacy, a switch to a second 
TNFi seems to be a reasonable option; though patients with detectable drug levels who 
fail are mainly primary failures, the TNF might not be the most relevant cytokine 
mediating their pathology(118). 
When less therapeutic options are available, the use of intensifications of 
biological drugs is more frequent(47,73,96,141,147). Bartelds et al. increased the Ada 
administration (40 mg sc weekly) in around 20% of RA patients due to inefficacy(47). 
Only 6 out of 20 ADA+ patients neutralized the antibodies after therapy intensifications 
but this strategy did not condition a relevant clinical improvement(47). In our cohort of 
RA and SpA patients under Ifx treatment, the need of therapy intensifications was more 
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frequent in ATI positive patients(73,96). In a previous study, it was seen that RA 
patients under Ifx frequently needed therapy intensifications but this modifications were 
not always enough to control the disease activity(159). When we investigated the 
efficacy of Ifx intensifications in a RA cohort under Ifx, stratifying by drug and/or ATI 
levels, similar findings to the previous study were found(141). These data suggest that 
therapy intensification of Ifx is limited in patients with inefficacy to the drug and the 
response is independent of the circulating drug levels(141).  
Once the correlation between drug levels and clinical response has been 
demonstrated, it would be very useful to know if there is a therapeutic range associated 
with a good clinical response. There are two studies from a Dutch group that define a 
therapeutic range for Ada in rheumatic patients(70,160). These studies are carried out in 
RA and PsA cohort, but both find that a therapeutic range between 5-8 µg/ml was 
associated with a good control of the disease activity(70,160). More limited data has 
been published about Goli due to a smaller sample size(102,89). In our article, Goli 
treated patients were categorized into quartiles depending on drug levels and clinical 
response was investigated(102). We observed that most non responders had serum Goli 
levels under 0.5 mg/L(102). Other publications propose a cut off for Ada or Etn to 
discriminate the capacity of remission(74,161). Although the cut off is similar in these 
two studies, no data has been published to confirm a concentration range. For Ifx in IBD 
patients there is a therapeutic range defined between 3-7 µg/ml(162) but for rheumatic 
diseases, there is not a clear therapeutic range. Previous publications have classified Ifx 
levels into high, medium and low levels but there is no consensus to establish limits in 
each of them(108,147,163). 
Some algorithms have been proposed to implement the use of drug and/or ADA 
levels monitoring in clinical practise(18,127,129,130,147,162,100). All these algorithms 
aim to improve the therapeutic decisions in clinical practice with accessory tools such as 
the monitoring of serum drug levels and/or ADA(18,127,129,130,147,162,100). Most of 
them correlate the clinical outcome (responder vs non responder) to serum drug 
concentrations (low, medium and high levels) and ADA status. To follow a therapeutic 
strategy based on each situation it is recommended to switch to another TNFi, switching 
to another biologic with a different mechanism of action or optimization strategies 
(increase or decrease the therapy regimen)(18,127,129,130,147,162,100). These 
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algorithms have not had much success in the field of rheumatology for several reasons: 
the lack of consensus to classify the levels into high, medium and low and the lack of 
prospective studies in rheumatic diseases designed for this purpose. In contrast, there 
exists a useful algorithm (TAXIT algorithm) for IBD patients treated with Ifx that has 
been obtained from a prospective observational study(162). In this algorithm, a 
therapeutic range (3-7 µg/ml) has been defined where no dose adaptation is 
required(162). 
 
Utility of TDM on optimization strategies 
 
In the last years, the use of tapering strategies is more and more frequent in 
rheumatic patients under biological drug treatment with a sustained control of the 
disease activity(131,133–135,137–140,142–145,164–171). With the accumulated 
experience over more than 15 years using biological drugs, our knowledge about these 
drugs has substantially increased in efficacy as well as in safety. Currently, it is clear 
when a biologic therapy should be initiated but it is unknown when it can be stopped. 
Several publications have emerged providing information on discontinuation or tapering 
strategies in RA or SpA patients(131,134,135,137–140,142–145,164–170,172–
177,171). Although some articles targeted to analyze this topic are heterogeneous and 
use different clinical outcomes, most of them conclude that in order to perform drug 
tapering in established RA and SpA patients, low disease activity must be sustained. 
The heterogeneity of the studies is very evident in our review over discontinuation or 
tapering in SpA patients: after reviewing 763 studies, only 13 articles fulfilled the 
criteria to be included(142). In this review, we confirmed that tapering strategy is 
successful in most SpA patients with a sustained LDA but discontinuation strategy is 
not recommended because it associates with a high number of flares(142).  
Even though more and more publications are emerging on this topic, 
rheumatologists are concerned about incidence of flares in patients under a tapering 
strategy and how to control them. Our group was the first one to compare long-term 
clinical outcomes in two cohorts of RA and SpA patients: one under a tapering strategy 
and other under a standard therapy regimen(143,144). In both publications, we observed 
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that the control of the disease activity is similar in both cohorts. In addition, the 
incidence of flares was comparable between cohorts and most of them were controlled 
with adjustments in administration interval(143,144). A progressive decrease of serum 
drug levels was observed during the tapering strategy, enough to maintain patients in 
LDA, suggesting that patients with LDA do need lower drug dose than patients with 
active disease. At the end of both studies, a higher number of ADA positive patients 
were detected in the tapering group (not significant for RA patients) but we could not 
demonstrate a correlation with the incidence of flares(143,144). This fact can be due to 
the small number of ADA positive patients in our studies(143,144).  
 
Economic repercussion of TDM 
 
The treatment with biopharmaceuticals represents a significant expense in our 
health system for several reasons, not only for their costs but also because their use is 
increasing and these treatments rarely discontinue. This issue involves that it is 
necessary to search feasible therapeutic strategies that allow our system to be 
sustainable. As we mentioned above, tapering strategies of biological drugs are more 
and more frequently used and can lead to relevant savings.  
In a cohort of 51 RA patients with Ifx, Van der Maas et al. observed that dose 
titration was feasible in patients with inactive disease and also demonstrated important 
cost savings with this strategy(167). Recently, two randomized controlled trials on 
tapering of Ada and Etn in RA patients performed in daily clinical practice have been 
published(139,140). Both clinical trials conclude that tapering is feasible in RA patients 
without impacting structural damage progression or the appearance of flares(139,140). 
To our knowledge, until our publication, no study comparing the same RA and SpA 
cohorts before and after the tapering strategy has been published(145). Moreover, the 
mentioned papers comprise only disease activity guided dose reduction (including 
radiographic progression and flares), none of them taking drug levels into 
account(139,140). In our cohort, we could see that patients with good response to a 
TNFi treatment may successfully respond to a tapering strategy, with subsequent 
diminished treatment costs(145). The routine monitoring of circulating drug levels can 
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be a useful tool that allows the optimization of drug administration over time, avoiding 
erroneous tapering strategies(145). Tailored treatment options will support patient 
confidence and treatment compliance, as well as providing support to health care 
systems, allowing them to spread their budgets over many more patients because of a 
more rational use. 
Our hospital was the first in Spain to use the serum drug and ADA levels 
monitoring in clinical practice. Prior to these determinations, when a therapeutic failure 
was detected, clinicians usually made empirical decisions, intensifying the current 
therapy regimen, switching to another TNFi or different class of drug. The disadvantage 
of choosing new biological therapies based only on clinical parameters is that it can lead 
to erroneous therapeutic decisions with the consequent clinical worsening of patients 
and the increase of financial costs. In our department, the optimization protocol for 
biolopharmaceuticals takes clinical (DAS28, EULAR response, BASDAI, ASDAS), 
serological (ESR, CRP) and structural (radiographic changes and ultrasonography) 
parameters into account and also includes the determination of serum drug and/or ADA 
levels.  
In the chapter 4, we show the important cost reduction detected in our hospital 
after tapering strategies of biologics(145,146). Serum drug and/or ADA determinations 
offer the possibility to tailor therapy according to individual needs and it aims at 
reducing delays in effective treatment or modifying treatment strategies. In the article 
13, costs per annual average-patient diagnosed with rheumatic disease show a 
pronounced decrease in two different periods: 2010-11 (-5%) and 2012-2013 (-
13%)(146). This reduction in cost occurs despite the fact that data regarding average-
dispensed-patients for the period 2010-2011 is similar, and that for the period 2012-
2013 it increases from 416-452 months(146). The implementation of the Royal Decree-
Law 4/2010 enforced in June 2010, resulted in a decrease of PTR of 7.5% for this type 
of medication. This Royal Decree-Law is the main cause for the decrease in costs in the 
period from 2010-2011(146). However, the decline in costs for the period 2012-2013 
can be mainly explained by the optimization of treatments with dose medications by 
adjusting dosage and intervals of administration(146).  
Important savings on biologics have been seen in other studies about 
optimization from our group, although this issue was not the main objective(143–146). 
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In our work comparing RA patients under a tapering strategy versus standard therapy 
regimen, we have observed a significantly lower quantity of the administered drug in 
the tapering group as compared to the standard therapy regimen, with an interval 
elongation of approximately 33% in Ifx, 53% in Ada and 53% in Etn(143). In our 
cohort of SpA patients under a tapering strategy comparing with a SpA cohort from the 
Netherlands under a standard therapy regimen, the tapering group showed an overall 
reduction of the administered drug at the end of the study(144). The dose reduction for 
Ifx was 22% and the interval was extended to 28.7%. The dose reduction was 45.2% for 
Ada and 51.5% for Etn(144).  
Pascual-Salcedo et al. investigated the same RA cohort in low disease activity in 
two different periods: a period with standard therapy regimen and a period under a 
tapering strategy(145). The main aim of this study was to analyze whether the clinical 
activity remains stable after a tapering strategy of TNFi in patients with LDA and to 
evaluate the potential benefit of this strategy on the treatment cost(145). Finally, it was 
concluded that the performance of a tapering strategy in our cohort of RA patients 
yielded considerable savings(145). These reduction of costs were similar to what has 
been described by others studies of drug tapering in RA(66,139,140,167). All this 
evidence on this topic demonstrates that clinicians are aware of having a sustainable 
health system providing the best possible care and treatment to their patients. In order to 
make the most accurate decisions, objective tools are needed to avoid undesirable 
clinical outcomes that have a direct and negative impact on the patient and, secondarily, 
an increase in health costs. 
Future 
 
This field of research still has many open fronts and its implementation in the 
clinic is currently little exploited. What needs to be done to make this tool shift from 
research to clinic? Firstly, there should be a consensus on the assays to measure drug 
and ADA levels between the different researching groups. At the moment, there is a 
European working group (MAGE), of which we are part that has targeted this issue as 
one of its priorities.  
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Nowadays, there is abundant information on the association between drug and/or 
ADA levels with clinical outcomes from different unicenter studies and most of them 
observational and/or retrospectives. Multicentre prospective studies are necessary to 
address the following issues: to find an optimal therapeutic range for each drug in the 
different pathologies, to make a clinic algorithm based on the therapeutic range and 
finally to demonstrate that working based on TDM is more accurate and effective than 
just with only clinical tools.  
Additionally, the role of monitoring serum drug and/or ADA levels in remission 
or low-activity patients undergoing optimization therapies is not well defined. Until the 
moment, all studies have included small observational studies from which it is difficult 
to draw robust conclusions. This type of therapeutic strategy is being increasingly used 
and in the coming years we will probably get more information about the utility of 
serum drug and/or ADA levels in this field.  
The current medicine tends to be personalized in order to make a more targeted 
and accurate treatment for each patient. This fact motivates that there is increasing 
research to define more clinical tools to identify different profiles of patients. The TDM 
has a main objective to follow this tendency and to ensure more effective therapeutic 
strategies in rheumatic patients under biological therapy.  
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English 
 
I. Lower serum Infliximab levels and the development of antibodies to Infliximab 
are associated with a poor clinical response, an earlier therapy discontinuation 
and an increased incidence of adverse effects in Rheumatoid Arthritis and 
Spondyloarthritis patients treated with Infliximab. 
 
II. The concomitant use of Methotrexate along with tumor necrosis factor inhibitors 
is useful to prevent anti-drug antibody development in Rheumatoid Arthritis and 
Spondyloarthritis patients. 
 
III. The effect of Infliximab treatment in patients with anti-drug antibodies has a 
relationship with the timing of the drug disappearance and anti-drug antibodies 
appearance between infusions, each resulting in different clinical consequences. 
 
IV. Serum Infliximab levels at the induction phase of the treatment might predict the 
group of patients that are more prone to develop antibodies to Infliximab and 
therefore, have a worse clinical course during the first year of therapy. 
 
V. The Tocilizumab standard regimen results in a wide variety of serum 
Tocilizumab trough concentrations between patients, and target binding seems to 
provide a better explanation for these variations than immunogenicity. Serum 
Tocilizumab levels are associated with C-reactive protein levels and clinical 
response.  
 
VI. Serum Golimumab levels are associated with the clinical activity and acute 
phase reactants in Rheumatoid Arthritis patients during the first year of therapy.  
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VII. The presence of antidrug-antibodies against the first tumor necrosis factor 
inhibitor is an influencing factor for the response to a second tumor necrosis 
factor inhibitor. The study of the immunogenicity in the biological treatment 
failure may help to predict the response to a second biological drug in 
Spondyloarthritis. 
 
VIII. Increasing the Infliximab dose in non-responding patients is expensive and was 
unsuccessful in our cohort of Rheumatoid Arthritis patients 
 
IX. Performing a tapering strategy in Rheumatoid Arthritis and Spondyloarthritis 
patients with low disease activity, along with a tight clinical control of the 
drug/anti-drug antibody levels, seems to be feasible and a cost-effective strategy 
without causing relevant clinical impact. 
 
Spanish 
 
I. La detección de bajos niveles de Infliximab y el desarrollo de anticuerpos anti-
fármaco se asocia con una peor respuesta clínica, aumento de frecuencia de 
abandono del tratamiento y una mayor incidencia de efectos adversos en 
pacientes con Artritis Reumatoide y Espondiloartritis tratados con Infliximab. 
 
II. El uso concomitante de Metotrexato con inhibidores del factor de necrosis 
tumoral es útil para prevenir el desarrollo de anticuerpos anti-fármacos en 
pacientes con Artritis Reumatoide y Espondiloartritis. 
 
III. El efecto de Infliximab en pacientes que ya han desarrollado anticuerpos anti-
fármaco se correlaciona con el momento de la desaparición del fármaco y la 
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aparición de anticuerpos anti-fármacos entre las infusiones, condicionando 
diferencias en la respuesta clínica.  
 
IV.  La monitorización de los niveles séricos de Infliximab en etapas tempranas 
puede predecir el grupo de pacientes más propensos a desarrollar anticuerpos 
contra Infliximab y tener un peor curso clínico durante el primer año de 
tratamiento.  
 
V. La administración de Tocilizumab a dosis estándar da lugar a una amplia 
variedad de concentraciones séricas del fármaco entre los pacientes, y la unión al 
objetivo parece proporcionar una mejor explicación de estas variaciones que la 
inmunogenicidad. Los niveles séricos de Tocilizumab se asocian con niveles de 
proteína C reactiva y respuesta clínica. 
 
VI. Los niveles séricos de Golimumab se asocian con la actividad clínica y los 
reactantes de fase aguda en pacientes con Artritis Reumatoide durante el primer 
año de tratamiento. 
 
VII. La presencia de anticuerpos anti-fármaco contra el primer inhibidor del factor de 
necrosis tumoral influye en la respuesta clínica a un segundo inhibidor del factor 
de necrosis tumoral. El estudio de la inmunogenicidad en el fracaso del 
tratamiento biológico puede ayudar a predecir la respuesta a un segundo 
tratamiento biológico en la Espondiloartritis. 
 
VIII. La estrategia de intensificación de dosis con Infliximab es costosa y no tuvo 
éxito en nuestra cohorte de pacientes con Artritis Reumatoide, 
independientemente de los niveles de fármaco en circulación antes de la escalada 
de la dosis. 
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IX. La estrategia de optimización de biológicos en pacientes con Artritis 
Reumatoide y Espondiloartritis en baja actividad mantenida, realizando un 
control clínico estrecho junto con la monitorización de niveles séricos de 
fármaco/anticuerpos anti-fármaco, parece una estrategia factible y rentable sin 
ocasionar un impacto clínico relevante. 
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